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The development of disease protein biomarkers and their use in clinical research have great
applications in the diagnosis, prognosis, and treatment of complex diseases. Mass spectrometry
methods for protein biomarker quantitation have recently gained importance in the early stages
of the biomarker pipeline, but their application in the validation phase is limited by their low
sample throughput. The technology of ultrathroughput mass spectrometry (uMS) transforms the
intrinsic quantitation capability of MS analyte multiplexing to sample multiplexing. Herein, the
novel MS-based bioanalytical platform utilized decoupled use of isotopic quantitation reference
standard and non-isotopic mass coding reagents to enable one-experiment quantitation of a target
protein biomarker candidate in multiple non-depleted serum samples. Screened repository of
signal-enhancing peptidyl reagents enabled N-in-1 analyses for a cost-effective, high sample
throughput strategy for protein biomarker validation applications. The signal enhancement and
sample multiplexing capability of the derivatization technique were then further investigated
within proteomic profiling and derived towards a global quantitative approach.
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Chapter 1. Introduction

1.1. The disease protein biomarker and the development pipeline

A biomarker, derived from the term “biological marker”, is defined by the National
Institutes of Health as “a characteristic that is objectively measured and evaluated as an indicator
of normal biological processes, pathogenic processes, or pharmacologic responses to a
therapeutic intervention”.1,2 The World Health Organization further described biomarker as “any
substance, structure, or process that can be measured in the body or its products and influence or
predict the incidence of outcome or disease”.3As objective measureable characteristics of
biological processes, any measured response - from blood pressure, pulse, basic blood chemistry
through complex tissue and blood composition, can serve as biomarkers.

Biomarkers have been mostly treated as surrogate endpoints (variables representing the
clinical state of an organism) when they are well-characterized, clinically evaluated, and
statistically validated. Despite the debates regarding the criteria for its utility, biomarker
discovery and its eventual development are rooted in two important clinical aspects: relevance
and validity. Ultimately, the candidate biomarker should both present clinically significant
information and reliable characterization of the efficacy as a marker.1 Increased recent scientific
efforts on the pursuit for effective biomarkers reflect their enormous potential to revolutionize
diagnosis, prognosis, and personalized treatment of almost every disease. Integrated omics
technologies and high-throughput methodologies have led to continually increasing studies on
the discovery of putative biomarkers.4
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Among the biological molecules that can qualify as biomarkers, proteins are most widely
studied.4 Tissue leakage proteins are carried onto the bloodstream and are therefore secreted into
other bodily fluids. In the diseased state, pathological functions of human tissues and organs are
affected and dysregulated. Proteins are highly dynamic and diverse molecules that greatly reflect
the biological differences based on the extent of the disease. Changes in the proteins associated
with the disease can include co/post-translational modification, cellular localization, interaction,
and activity.5

The biomarker pipeline, illustrated in Figure 1.1, commences with the discovery of
putative biomarkers for a certain disease or condition. Upon further characterization and
evaluation, increasing numbers of samples are analyzed for the verification and validation phases
where more targeted methods are required. The long path from discovery to validation, in terms
of cost and time, is comparable to a candidate drug development. The development of validated
biomarkers that have already received Food and Drug Administration (FDA) approval such as
human epididymis 4 (ovarian cancer), interleukin 1 receptor-like 1 protein (heart failure), and
tryptase (mastocytosis) spanned from 8 to 20 years.1,4

Figure 1.1. The protein biomarker pipeline.
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1.2. Protein biomarker discovery from quantitative proteomic profiling

1.2.1. Discovery of novel biomarkers

As increased scientific efforts have been spent to discovering novel biomarkers, potential
protein biomarkers and their discovery rely on reliable determination of their quantitative
changes in healthy and diseased samples. The progression of the disease signified by the changes
in the protein requires accurate and precise quantitative measurements in biological samples.
Typically, the non-targeted aspect of the discovery phase entails fold changes or up/downregulation results.6 Compared to high-abundant proteins in sera or plasma, many novel protein
biomarkers have low concentration, usually in the low nanogram range. As such, in the initial
stage of discovery, it is only practical to utilize tissue samples or other body fluids in close
proximity or within the diseased organ of the individual. Despite being obtained from more
invasive clinical sampling, the analysis enables determination of relevant proteins that are varied
between control and diseased specimens.7 From these samples, sufficient limits of detection or
quantitation are attained to produce a global quantitative profile for the identification of certain
potential biomarkers that have significant changes.

1.2.2. Mass spectrometry-based technologies for proteomic quantitation

Quantitative profiling of dissected tissue samples using mass spectrometry methods for
biomarker discovery are based on sample libraries such as post-mortem formalin-fixed paraffinembedded (FFPE) tissues. Sectional analysis on differential protein expression can be performed,
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as well as comparative studies among sections from the same tissue.8 Human proximal fluids are
also ideal samples in examining variations in proteomic profiles for a specific disease. Analysis
of gastric fluid, interstitial and peritoneal fluid, and urine9-12 had revealed distinct protein profiles
and were examined for the discovery of novel biomarkers. Observable changes or occurrence of
a protein isomer can also be indicative of a diseased state, as reported in the case of Alzheimer’s
disease enzyme production.13 Moreover, recent reports have shown changes in post-translational
modifications associated with dysregulated pathological functionalities and disease progress.14-16

Over the past years, mass spectrometry (MS)-based proteomic analyses have generated
thousands of potential disease biomarkers. Following initial proteolytic digestion of proteins, the
surrogate peptides are quantified, which signifies the basis of relative quantitation: a bottom-up
approach (also known as shotgun proteomics). Methods in the quantitative proteomics toolbox,
shown in Figure 1.2, including more recently developed techniques, are mainly classified as
label-free and derivatization-based (under Common Technologies).

4

Enzymatic 18O-Labeling

Chemical Tagging of Stable
Isotope Labels
Common Technologies
Metabolic Labeling

Label-free

Quantitative Proteomic
Profiling of Human
Proteome Samples

Differentially-Expressed
Proteins

Protein Biomarker
Discovery

Disease-Specific Protein
Isomers

Abnormal Protein Activities

Figure 1.2. Quantitative proteomic tools for discovering protein biomarkers (adapted
from book chapter, “Quantitative Proteomics in Development of Protein Biomarkers” by Yao, et
al in Proteomic and Metabolomic Approaches to Biomarker Discovery).5

Label or derivatization-based methods have been continually explored recently. An
important labeling method, the enzymatic
technique that incorporates two atoms of

18

18

O-labeling of peptides, is a simple and sensitive

O at the peptide C-termini.17,18 Usually applied for

comparative quantitation, protein digests are labeled through incubation with proteases in buffers
made of H218O or H216O. The method is typically employed for the investigation of proteins of
interest in diseased and control samples. As the control sample can be used as the master control
for the analysis, the enzyme-catalyzed technique was further utilized for preparation of a global
reference standard for biomarker discovery.19 Co- and post-translational modifications can also
5

be investigated from MS results of labeled proteotypic peptides.20,21 The labeling is both robust
and inexpensive, without extensive cleanup and complex sample processing steps. Moreover,
18

O-water serves as the reagent and is added in large excess, providing rapid and efficient

labeling mechanism. More recent application of this method involved 18O-labeling of biological
samples such as plasma, sera, and microdissected tissue.19,22,23

Discovery of potential biomarkers from biological samples imposes good sensitivity and
accurate quantitation within a meaningful number of diseased and control samples, as clinical
variability is an essential factor to consider.24 To improve accuracy and multiplexing of multiple
samples, chemical tags with stable isotope labels are available to differentially code each sample,
respectively. These reagents, which can be commercially purchased, provide simple and
straightforward sample processing protocols.

1.3. Protein biomarker validation

1.3.1. Current high sample throughput methods

Reliable detection and quantitation of candidate protein biomarkers are performed
through bioanalytical platforms that have the capability to measure analytes in complex
biological samples. In the discovery phase of biomarker development, the analysis requires
multiplexed quantitation of multiple proteins in a small number of samples. Potential biomarkers
are then subsequently identified, qualified, and verified before validation phase ensues. MS
methods for multiplexed protein quantitation in complex biological samples have been essential
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in the discovery phase of the biomarker pipeline.5,25 As candidate biomarkers advance through
the validation phase, however, the mode of analysis should be transformed to facilitate increased
number of samples wherein fewer analytes are quantified. The sample throughput bottleneck
limits the current mass spectrometry methods in the validation phase of protein biomarker
development. Typically during validation, the analysis requires high sample throughput targeted
protein quantitation, where clinically significant number of biological samples can be processed.7

Currently, the gold standard methods for the validation of protein biomarkers are
conducted using immunograde antibodies and immunoassays such as enzyme-linked
immunosorbent assay (ELISA).26 These techniques, however, are costly and lengthy to develop;
they also involve production of a specific immunograde antibody for a candidate protein
biomarker, making them non-flexible for other candidates.27 Usually in validation studies
involving thousands of patient-control samples, less than ten protein candidates are analyzed. In
addition, an immunoassay necessitates a single immunograde antibody for one candidate,
making it even more expensive for verifying and validating those candidates without existing
immunograde antibodies.

Clinical sampling for validation takes into account the accessibility and invasiveness of
the patient sample collection. The samples of choice are blood and other easily sampled body
fluids. At this point, candidate biomarkers resulting from tissue or proximal fluid discoveries are
diluted in the bloodstream, and their concentrations are in the range of low nanograms per
milliliter. This amount, contained in the human plasma sample, has to be analyzed within all
other proteins of which concentrations span up to 12 orders of magnitude.28,29

7

1.3.2 Utilizing mass spectrometry for multiplexed quantitation

Protein quantitation methods involving label-free and chemical derivatization approaches
in mass spectrometry have become increasingly important in the analysis of complex biological
samples.30,31 To increase the sample throughput potential of the analysis, chemical
derivatization-based methods introduce chemical tags, facilitating simultaneous quantitation in a
single analysis. Protein quantitation methods that utilize chemical derivatization are generally
classified into isobaric and mass-difference tagging approaches.

Mass spectrometry-based quantitation methods for proteins involving isobaric and massdifference tagging reagents have been continually explored on the basis of ease of preparation
and reduced analysis cost. Identification and relative quantitation of proteins using these reagents
are carried out in single-stage mass spectrometry analyses or tandem MS (MS2 or MS3)
experiments. Table 1.1 lists the reagents and the multiplexing capability comparison of each
technique. Commercially available 4-plex and 8-plex isobaric tags for relative and absolute
quantitation (iTRAQ)32, 6plex and 10-plex tandem mass tags (TMT)33-35, as well as variant mass
tags dimethylated leucines (DiLeu)31, deuterium isobaric amine reactive tags (DiART)36,37, solid
phase isobaric mass tagging (SPIMT)38, mass-balanced isotope dipeptide tags (MBIT)39,
cleavable isobaric labeled affinity tag (CILAT)40, isobaric peptide termini labeling (IPTL)41, and
pseudo-isobaric dimethyl labeling (pIDL)42 are among some of reported isobaric reagents used.
On the other hand, examples of mass-difference tagging reagents include isotope-coded protein
label (ICPL)43, isotope-coded affinity tag (ICAT)44, neutron-encoded chemical labels
(NeuCode)45, and reductive methylation46-48 approaches. However, although labeling is highly
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efficient, both isobaric and mass-difference tagging reagents require isotope labels to increase
their sample throughput potential. Furthermore, the high cost of commercial isobaric reagents
limits their application as routine MS-based quantitative proteomics tool.30,49

9

Table 1.1. Multiplexing in mass spectrometry for quantitative analysis.
Reagent

Required Resolving
Power of Instrument

Quantitation
Mode

iTRAQ

-

MS2

TMT

MS used

Multiplexing

References

MALDIMS/MS

8-plex

Pottiez, et al32
2012

MS2 minimum
MS2
35,000 and 30,000 at
200m/z

Q Exactive
Orbitrap and
Orbitrap
Elite

10-plex

Werner, et al35
2014

MS1 120,000; MS2
quant 60,000

MS2

Orbitrap
Fusion

10-plex

Erickson, et al50
2015

MS2 30,000, MS3
performed

MS3

LTQ
Orbitrap

6-plex

Ting, et al51 2011

Hyperplexed mass tags
(SILAC + TMT)

MS1 30,000; MS2
7,500

MS2

LTQ
Orbitrap
Velos

54-plex (18plex of 3
targets)

Everly, et al52,53
2013

DiLeu (Dimethylated Leucines)

MS1 120,000; MS2
60,000

MS2

Orbitrap
Elite

12-plex

Frost, et al54 2015

-

MS2

IM-MS/MS

4-plex

Sturm, et al55 2014

DiART (deuterium isobaric amine reactive tags)

MS2

LTQ
Orbitrap

4-plex

Ramsubramaniam,
et al37 2013

MBIT (mass-balanced isotope dipeptide
tag)

MS2

MALDI
MS/MS

2-plex

Suh, et al56 2011

-

10

CILAT (cleavable isobaric labeled affinity
tag)

-

MS2

MALDIMS/MS

12-plex

Zeng, et al40 2009

IPTL (isobaric peptide termini labeling)

MS1 70,000 and
MS2 35,000

MS2

Q Exactive
Orbitrap

3-plex

Koehler, et al41
2013

pIDL (pseudo-isobaric dimethyl labeling)

MS1 60,000 and
MS2 30,000 (mass
defect-based)

MS2

LTQ
Orbitrap
Velos

4-plex

Zhou, et al42 2013

PAL (protected amine labels)

MS1 240,000 and
MS2 30,000

MS2

LTQ
Orbitrap

6-plex

Ficarro, et al57
2014

cPILOT (combined precursor isotopic
labeling and isobaric tagging) and
cysDML (cysteine-selective dimethyl
labeling)

MS1 60,000

MS2

LTQ Orbitap
Velos

12- to 16-plex

Evans and
Robinson 2013,
Gu, et al58,59 2015

CIT (Caltech isobaric tags)

-

MS2

LTQ
Orbitrap

2-plex

Sohn, et al60 2012

NeuCode

MS1 survey 30,000;
MS2 quant
scan 480,000 (mass
defect-based)

MS2

Orbitrap
Elite

12-plex

Hebert, et al45
2013

Dimethyl labelling

-

MS2

-

5-plex

Wu, et al46 2014
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1.3.3. The sample throughput limitation of current mass spectrometry methods

Contrary

to

antibody-based

methods

such

as

Western-blot,

ELISA

or

immunohistochemistry, MS-based methods do not require immunograde antibodies developed
for individual or panel of proteins. However, the capability of the application of current
quantitative reagent toolbox after the discovery phase can be arguably conceded since their
utility is not ideal for targeted quantitation in multiple samples.61 The mode of selected reaction
monitoring (SRM) MS, or multiple reaction monitoring (MRM) MS provide multiplexing
capability to analyze multiple analytes in one sample. In terms of sample (throughput)
multiplexing, existing MRM methods have low sample throughput. The sample throughput has
been limited to three, where the isotopic reagents used for labeling are iTRAQ counterparts,
called mTRAQ. The structures of mTRAQ are shown in Figure 1.3, where the peptide reactive
group is shown in green, and the isotopic variants in pink. 25

Δ0

Δ4

Δ8

Figure 1.3. Structure of mTRAQ reagents for triplex analyte and sample multiplexing in MRM.
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1.4. Multiple reaction monitoring mass spectrometry

1.4.1. Overview and the multiplexing potential of MRM methods

Clinical and industrial applications of MRM MS exploit the enhanced accuracy and
specificity of the method for analyte quantitation. MRM modes of analysis are performed on
triple quadrupole (QqQ), where Q1serves as the first mass analyzer, q2 as collision cell, and Q3
as the second mass analyzer. Quantitation is achieved in tandem fashion by monitoring
transitions of precursor ion (peptide) to fragment (b- or y-) ions.62 Fragmentations wherein the
charge is retained in the N-terminus are called b-ions, while y-ions carry the C-terminus. Figure
1.4 depicts the schematic for transition monitoring: analytes of interest are selected in Q1,
fragmented, and finally, specified fragments are analyzed in Q3.

Figure 1.4. The precursor-to-fragment transition diagram in MRM analysis.
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As mentioned, current MS methods such as MRM are capable of multiplexed analysis of
multiple proteins in a single sample. More recently, MRM-based multiplexed quantitation of
more than a hundred proteins in plasma samples has been reported. The application of such
methods in the later validation phase, however, is inhibited by their low sample throughput. 7

1.4.2. Ultrathroughput multiple reaction mass spectrometry

A novel technology developed in our research laboratory, called Ultrathroughput
Multiple Reaction Monitoring MS (uMRM MS), is an integration of non-isotopic peptide
derivatization and liquid chromatography (LC) stable isotope dilution (SID) MRM MS. 49 uMRM
MS breaks through the bottleneck of the low sample throughput of all MS methods, transforming
the standard MRM technique into a high-throughput potential that allows for one-experiment
quantitation of a target protein (or several proteins) in many human serum or plasma samples. It
can then be optimized and further utilized for the validation of candidate biomarkers in large
numbers of patient samples for clinical applications.

1.5. Dissertation objectives and goals

1.5.1. Targeted quantitative analysis for cancer biomarker validation via N-in-1
ultrathroughput MS

This work presents a new cost-effective technology that integrates MRM and peptide
derivatization (labeling or tagging) using a library of in-house synthesized non-isotopic reagents
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to quantify low-abundant model protein biomarker in multiple samples. The derivatizing
reagents, termed peptidyl reagents, are short peptides bearing varied N-termini modifications.
Peptidyl reagents have high structural tunability and can be readily prepared through inexpensive
solid-phase peptide synthesis. When sample-specific derivatization of signature peptides is
achieved, a one-experiment MRM analysis of pooled samples will enable a high sample
throughput quantitation of the target protein biomarker.

Typically in validation studies involving thousands of patient-control samples, less than
ten protein candidates are analyzed.7 The uMRM technology offers the following advantages as a
bioanalytical platform: sample throughput advantage, flexibility, and immediate impact. Unlike
current gold standard immunoassays for biomarker validation, uMRM is mass spectrometrybased technique; thus it does not require the use of immunograde antibodies and is faster and
more economical to develop. Figure 1.5 compares uMRM and ELISA workflows. In this study,
the novel approach can be adapted in such ways that it is flexible across different biomarker
candidates. The innovative nature of uMRM principle can also be translated to take advantage of
the latest mass spectrometry instrumentation, as it is not limited to the use of conventional
instruments for MRM measurements. It transforms the intrinsic MS capability of analyzing
multiple analytes in a single experiment into the sample throughput dimension that will quantify
common analytes in multiple samples.
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1.5.2. Utilizing peptide derivatization technique for global targeted proteomic applications

Peptide derivatization using peptidyl reagents offers signal enhancement for increased
analytical detectability in mass spectrometry. Thus, the signal enhancement and sample
multiplexing capability of the derivatization technique were then further investigated within
proteomic profiling and derived towards a global quantitative approach.

Figure 1.5. Highlighting the advantages of uMRM in comparison with ELISA.
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Chapter 2. Peptide derivatization using peptidyl reagents for high signal yield screening

2.1. Introduction

Mass spectrometry (MS), combined with front-end separation techniques, is intrinsically
capable of examining large numbers of analytes in a single experiment. These analytes can either
be different molecules in a particular sample (analyte multiplexing) or common molecules that
carry sample-specific mass tags (sample multiplexing). In the latter case, mass tagging is
achieved via differentially labeling analytes with stable isotopes in a sample-specific manner; the
isotope incorporation can be metabolic, enzymatic, or chemical.1 The relative mass spectra
intensity of the differentially-tagged molecules allows for quantitation. In the protein biomarker
regime, the analytes are peptides that result from proteolytic treatment of human proteome
samples, e.g., sera, and these peptides are used as quantitation surrogates. Sample-specific
tagging of common peptides in different samples can be achieved by chemical derivatization of
peptides using isotopic reagents. There are collections of commercial and research-grade isotopic
reagents in the toolbox of mass spectrometry-based quantitative proteomics. Quantitation of the
isotope-labeled peptides are carried out by single-stage analysis using mass-difference tagging
reagents, or using isobaric tagging chemicals for tandem MS (the so-called MS2 or MS3)
experiments to monitor quantitation reporter ions produced from differentially-tagged peptides.

Multiplexing samples for a single experiment, or increasing the sample throughput for
MS analysis, is continuously being pursued. Utilization of the mass defect of peptide fragment
ions for multiplexed proteomic quantitation becomes feasible using isotopologues of commercial
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reagents and can be credited to contemporary high-resolution mass spectrometers. Small
differences in the mass defect of quantitation reporter ions can now be readily resolved.2 A
common challenge for the isobaric mass tagging strategy, however, originates from the coselection of precursor ions that have close retention time and mass-to-charge ratios. This coselection leads to compressed ratios of the reporter ions,3 because all peptides in a particular
sample are derivatized with the same reagent. Methods of MS3-based quantitation and gas-phase
purification4 have been proposed to address this issue, but at the expense of relatively reduced
sensitivity.5 Further increases in the sample throughput of MS analysis can exploit a modular
principle for workflow design, through the combined use of the isotopic quantitation reference
and peptide derivatization. Hyperplexed proteomic quantitation of 18 samples, using isotopic
reagents, has been presented.6,7 Also reported was a proof-of-concept demonstration of oneexperiment quantitation of 25 samples using non-isotopic reagents for peptide derivatization.8
Sequential labeling of peptides with dual sets of isotopic reagents provides yet another route to
increase the sample throughput for MS analysis, allowing for multiplexing of 12-16 samples.9,10

However, it is expensive to use isotopic reagents for multiplexing analysis of large
numbers of samples. The cost of analysis increases more than proportionally with the sample
number increase. The structural diversity of isotopic reagents that can be economically
synthesized is also limited. Furthermore, quantitation of low-abundance proteins in sera requires
large sample volumes in order to enable MS analysis with desired quantitation limits; it becomes
cost-prohibitive to use isotopic reagents to derivatize peptides in the digests of human sera in
large volumes (e.g., 100 µL) and large numbers (100’s to 1000’s).
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Setting aside the multiplexing requirement, simplistic chemical modification of peptides
had long been performed in MS approaches. Chemical modification is performed to achieve
three major goals: (1) to introduce quantification labels, (2) to enhance spectral signals of
proteotypic peptides, and (3) to simplify the complexity of spectral data.11 Techniques for the
modification of the peptide termini, both N- and C-terminal, enabled global analysis of
proteomes. The N-termini have gained more popularity as modification target. Modification in
the N-terminal had been categorized, through a set of labeling experiment utilizing Iodinecontaining compounds for derivatization reactions.12 Generally, they are grouped as passive and
active fragment ion mass defect labeling (FIMDL). Their classification is based on the
fragmentation behavior of the peptide, whether or not the modifying group affects the gas-phase
fragmentation. FIMDL modifying groups can be observed in the spectrum depending on charge
distribution and consequently the relative abundance of generated fragment ions.

Herein, the techniques of simple chemical modification are adapted to prepare short
peptides (modified), termed peptidyl reagents, and subsequently use them as derivatizing tools
for quantitation. Short peptides will be prepared through standard Fmoc-chemistry solid phase
peptide synthesis using trityl polystyrene resins preloaded with the first amino acid. After the last
deprotection step, with the peptides still bound to the resin, the free N-terminal will be modified
with various capping reagents. The products will then be used to derivatize standard signature
peptides of model biomarkers, prostate specific antigen (PSA) and cystic fibrosis transmembrane
conductance regulator (CFTR).
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Prostate specific antigen, other names include Kallikrein-3, Gamma seminoprotein, P-30
antigen, and semenogelase (www.uniprot.org), is a widely used protein biomarker for prostate
diseases such as prostate cancer and benign prostatic hyperplasia. Its function is to hydrolyze
semenogelin-1, thus liquefying the seminal coagulum.13,14 On the other hand, the deficiency of
protein CFTR in plasma membrane expression and function results in diminished chloride ion
transport, consequently developing into pathological progression of cystic fibrosis.15
Derivatization methods will be developed for PSA and CFTR01 signature peptides, and will then
be further validated for increased sample throughput application.

2.2. Preparation of peptidyl reagent library

2.2.1. Experimental

2.2.1.1. Research Facilities

All sample preparations were performed in a Biosafety Level 2 laboratory within the
Department of Chemistry (R409 and R411, Xudong Yao Lab, Chemistry Building). MS
characterizations are performed using AccuTOF DART MS (JEOL), located in the MS facility of
the Department of Chemistry (R403).

25

2.2.1.2. Materials and reagents

Pre-loaded 2-Cl-trityl polystyrene resins, Fmoc L-amino acids were obtained from Matrix
Innovation (Quebec, Canada).

Solvents dimethylformamide (DMF), dimethylacetamide

(DMAc), dichloromethane (DCM), tetrahydrofuran (THF), methanol (MeOH), LC-MS grade
acetonitrile (ACN), and diethylether were purchased from Sigma-Aldrich (St. Louis,
MO).

Fmoc-β-Ala-OH, Fmoc-4-Abu-OH, and Fmoc-5-Ava were purchased from Advanced

ChemTech
phosphate

(Louisville,
(HBTU)

was

KY).

O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-

obtained

from

Chem

Impex

(Wood

Dale,

IL).

N,N-

Diisopropylethylamine (DIEA), N-Methylmorpholine (NMM), piperidine, acetic anhydride,
propionic anhydride, valeric anhydride, formaldehyde, pyridine-borane complex, 2-picolineborane complex, acetic acid, O-phthaldialdehyde (OPA), dimethylaminobenzoic acid (DMABA),
diethylaminobenzoic acid (DEABA), picolinic acid, triisopropylsilane (TIPS), potassium cyanide
(KCN), ninhydrin, and ethanol (EtOH) were also from Sigma-Aldrich (St. Louis, MO). Pyridine
and phenol were from J.T. Baker (Center Valley, PA). Glutaraldehyde (Gl), trifluoroacetic acid
(TFA), and formic acid (FA) were purchased from Fisher (Pittsburgh, PA).

Peptide synthesis was performed in 2-frit, 20 µm extraction reservoirs (UCT, Bristol,
PA). Direct-Q3 water system (Millipore, Billerica, MA) was used to purify deionized water.
Samples were dried using SpeedVac (Savant, Farmingdale, NY), vacuum oven (Fisher
Scientific, Pittsburgh, PA) or lyophilizer (Labconco, Kansas City, MO). Incubation of samples
was performed on Hula Mixer (Invitrogen, Grand Island, NY) or Thermomixer R (Eppendorf,
Hauppauge, NY).
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2.2.1.3. Fmoc-based solid-phase peptide synthesis of short peptides

Solid-phase peptide synthesis (SPPS) was performed on 2-Cl trityl polystyrene resin
preloaded with amino acid. In a clean tube, a solution containing Fmoc-amino acid (3-fold
excess), HBTU (3-fold excess), and DIEA (5-fold excess) in DMF were prepared. The solution
was added to the polystyrene resin contained in a fritted reservoir, previously swelled with DMF
and drained. The coupling step was performed by incubating the reaction mixture for 90 mins at
room temperature, and washed with DMF, DCM, MeOH, and DMF. Fmoc-deprotection was
carried out by incubating the resin with 25% piperidine in DMF for 90 mins. Coupling and
deprotection steps correspond to one cycle of synthesis. The resin was then washed with DMF,
DCM, MeOH, DMF, and diethyl ether. After a series of coupling cycles, the polystyrene resin
with bound short peptides, were dried in vacuum and stored at 4°C.

The completion of each reaction step in SPPS can be visualized through Kaiser Test.
Solution A was prepared from ninhydrin:EtOH [5:95 (w/v)], Solution B from phenol:EtOH [4:1
(w/v)], and Solution C from 1 mM KCN in H2O:pyridine [2:98 (v/v)]. Kaiser test was
performed by transferring 1-2 mg of resin in a clear microcentrifuge tube. Two drops of Solution
A, one drop of Solution B, and one drop of Solution C were added to the resin, respectively. The
tube was then heated for 2-5 mins. Blue resins correspond to free amines, while clear/yellowish
resins indicate protected N-terminal.
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2.2.1.4. On-resin N-terminal modifications

After a series of coupling cycles to prepare short peptides on-resin, various solid-phase
N-terminal capping modifications (described below) were developed to generate the library of
peptidyl reagents. In a separate tube, cleavage solution was prepared by mixing TFA:TIPS:H2O
[900:50:50 (v/v/v)]. The cleavage solution was added to the reservoir containing dried resin and
cooled in an ice bath for 10 mins. The reaction mixture was then incubated for 90 mins, followed
by draining of peptide solution in a clean microcentrifuge tube. TFA was concentrated in
vacuum oven, followed by precipitation of peptides in cold ether. The peptides were dried in
SpeedVac and lyophilizer before storing them in -20°C.

Acylation with anhydrides. In a microcentrifuge tube, a solution containing 50 µL
acetic, propionic, or valeric anhydride, 60 µL DIEA, and 890 µL DMF was prepared and added
to 100 mg of dried resin with short peptides. The reaction mixture was incubated overnight.
After incubation, the solution was drained from the reservoir. The resin was then washed, dried
and peptidyl reagents were cleaved as described in the above procedure.

Acylation with picolinic acid. In a microcentrifuge tube, a solution containing 29 mg
picolinic acid, 88 mg HBTU, 50 µL DIEA and 1 mL DMF was prepared and added to 100 mg of
dried resin with short peptides. The reaction mixture was incubated overnight. After incubation,
the solution was drained from the reservoir. The resin was then washed, dried and peptidyl
reagents were cleaved as described in the above procedure.
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Acylation with diethylaminobenzoic acid. In a microcentrifuge tube, a solution
containing 173 mg DMABA, 350 mg HBTU, 200 µL DIEA and 1 mL DMF was prepared and
added to 100 mg of dried resin with short peptides. The reaction mixture was incubated
overnight. After incubation, the solution was drained from the reservoir. The resin was then
washed, dried and peptidyl reagents were cleaved as described in the above procedure.

Dimethylation. To 100 mg of dried resin with short peptides, 286 µL formaldehyde,
1080 µL MeOH, 246 µL pyridine-borane complex, and 132 µL acetic acid were added
successively. The reaction mixture was cooled in ice for 10 mins. Overnight incubation with
gentle swirling was performed. The reservoir cap was punctured to release gas buildup. After
incubation, the solution was drained from the reaction mixture. The resin was then washed with
MeOH, dried, and peptidyl reagents were cleaved as described in the above procedure.

Dialkylation with glutaraldehyde. In a clean tube, a solution containing 704 µL
glutaraldehyde, 352 µL THF, 704 µL MeOH, 246 µL pyridine-borane complex, and 132 µL
acetic acid was prepared and added to 100 mg of dried resin with short peptides. The reaction
mixture was incubated overnight. After incubation, the solution was drained from the reservoir.
The resin was then washed with MeOH, dried, and peptidyl reagents were cleaved as described
in the above procedure.

Dialkylation with OPA. In a microcentrifuge tube, a solution containing 89 mg OPA
and 142 mg 2-picoline-borane complex in 667 µL MeOH was prepared and added to 100 mg of
dried resin with short peptides. The reaction mixture was incubated overnight. After incubation,
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the solution was drained from the reservoir. The resin was then washed with MeOH, dried, and
peptidyl reagents were cleaved as described in the above procedure.

2.2.1.5. Split-and-pool preparation of peptidyl reagent sets

To facilitate synthesis of several peptidyl reagent sequences in one mixture for screening
purposes, each set of peptidyl reagents was prepared by performing split and pool method;
starting on equal molar amounts of resins pre-loaded with different amino acids. Typically, a
total of 1 g resin was split into 2 to 5 fractions. The resins were split evenly and transferred into
reservoirs, followed by successive coupling cycles with different amino acids. After drying, the
resins were recombined and split for the next coupling cycles, diagrammed in Figure 2.1.
Subsequent common N-terminal capping modification, acid cleavage, and precipitation were
then performed. The reagents were dried in SpeedVac and lyophilizer, followed by
characterization in AccuTOF DART MS. From sets of reagents prepared for screening, a
representative list is shown in Table 2.1.
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Figure 2.1. Split-and-pool preparation of peptidyl reagent sets. A, B, C,…m are amino
acids constituting multiple sequences in one pool.

Table 2.1. Representative peptidyl reagents screened for uMRM analysis.
Dimethyl

Propionyl

Acetyl

Picolinoyl Pyrrolidin-1-yl Isoindolin-2-yl

4-(Diethylamino)
benzoyl

Dim-βAL

Pr-AFA

Ac-FVG Pic-GGA

Gl-VAL

OPA-VFF

DEABA-GGG

Dim-βAG

Pr-AGA

Ac-FFG

Pic-GFG

Gl-VAV

OPA-VLG

DEABA-GLG

Dim-βAA

Pr-ALA

Ac-FLG

Pic-GGG

Gl-VVG

OPA-VGA

Dim-βAVA Pr-AFG

Ac-FLL

Pic-GLG

Gl-VVA

OPA-VFA

Dim-βAVG Pr-AGG

Ac-VVV Pic-GGF

Gl-AFVL

Dim-βAAVG Pr-VGVA Ac-VLV Pic-GAVV Gl-AFVF
…

…

…

…

…
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2.2.2. Results and discussion

To develop a repository of reagents that can efficiently derivatize proteome digests,
design and synthesis of short peptides with various N-terminal capping groups were performed
using a screening-based strategy.16,17 Following a series of coupling cycles to synthesize the
short peptides, various solid-phase N-terminal modifications or capping (denoted as CapGr) were
performed to generate the library of peptidyl reagents. These short peptides having modified Nterminal, with a general form of CapGr-AAn…AA1 (n = 2, 3 or 4), comprise the peptidyl reagent
library and are termed peptidyl reagents. Figure 2.2 shows the structures of N-terminal reagent
modifying groups. Protocols for in-solution derivatizations obtained from literature needed to be
modified and developed though solid-phase methodologies.12,18-22

For a simplistic approach, only Fmoc-amino acids with no reactive side chains (alanine,
glycine, leucine, phenylalanine, and valine) were used in this study. The peptide length was also
limited to a maximum of four amino acid residues, and the N-terminus was capped to convert the
primary N-terminal amine into groups that are inert during derivatization of proteome digests.
Specifically, the N-termini of peptidyl reagents were capped with seven different functional
groups through either acylation [acetyl, propionyl, picolinoyl, and 4-(diethylamino)benzoyl] or
reductive dialkylation [dimethyl, pyrrolidin-1-yl (the product of glutaraldehyde), and isoindolin2-yl (the product of phthalaldehyde)]. For screening purposes, the reagents were prepared using
split-and-pool strategy to generate a large number of reagents. The split-and-pool synthesis
technique23 was used to prepare small libraries of peptidyl reagents on the small scale, starting
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with 1 g of a mixture of trityl-Cl polystyrene resin preloaded with the first amino acid (equal
moles); where each library contained 6-12 reagents.

Figure 2.2. Selected N-termini modifications on the peptidyl reagents. These modifications
served as N-terminal capping groups to increase the diversity of reagent repository.

2.2.2.1. Optimization for improving the yield of the peptidyl reagent synthesis

For comparison of dimethylation yield, the ideal composition and reagent ratio of
modification solution were developed (Table 2.2). The resulting peptidyl reagent was cleaved
from the resin and analyzed in MS. Ratio of dimethylated to unmodified peptide was found to be
highest with 57:108:49:26.4 (CH2O/MeOH/PyB/HOAc) solution and overnight incubation at
room temperature.
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Table 2.2. Optimization results for on-resin dimethylation. Reaction yield is shown as a ratio of
modified to unmodified peptidyl reagent, as analyzed by MS.
Modification solution

Unimethylated: Dimethylated:
unmodified

unmodified

114:216:49:48 (CH2O/MeOH/PyB/NMM), O/N, RT

14:1

59:1

57:108:49:48 (CH2O/MeOH/PyB/NMM), O/N, RT

36:1

146:1

57:108:49:48 (CH2O/MeOH/PyB/NMM), 2h, RT

15:1

78:1

57:108:49:26.4 (CH2O/MeOH/PyB/HOAc), O/N, RT

40:1

666:1

57:108:98:48 (CH2O/MeOH/PyB/NMM), O/N, RT

52:1

134:1

The same optimization was performed for glutaraldehydation, shown in Table 2.3. The
highest intensity ratio of glutaraldehydated to unmodified peptide was obtained from
141:70:141:49:26 (Gl/THF/MeOH/PyB/HOAc) solution and overnight incubation at room
temperature. Attempts were made to generate more modification schemes for increased number
of reagents. With succinic dialdehyde modification, the compound was synthesized in-house.
Optimized procedure with 10:40:50 (HOAc/MeOH/2,5-dimethoxytetrahydrofuran) solution
incubated at 37°C for overnight resulted to higher yield in the MS. However, when used for onresin modification of peptide, the yield was only 0.6:1 (modified/unmodified).

Alkylation reactions with butyraldehyde and hexanaldehyde, as well as modification with
dimethylaminobenzoic acid were also developed, but the on-resin preparation methods were
inefficient. To recount the methods, the following were performed for the unsuccessful
modifications and would thus require optimization if adapted. The corresponding solutions were
prepared and added to 100 mg of dried resin with short peptides, followed by overnight
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incubation, washed, and cleaved as per protocol. For alkylation with butyraldehyde, a solution
containing 752 µL butanal, 540 µL MeOH, 123 µL pyridine-borane complex, and 76 µL acetic
acid was prepared. With hexanaldehyde, the solution contained 541 µL hexanaldehyde, 540 µL
MeOH, 123 µL pyridine-borane complex, and 76 µL acetic acid. Lastly, for the modification
using dimethylaminobenzoic acid, the incubating solution consisted of 148 mg DMABA, 350 mg
HBTU, 200 µL DIEA and 1 mL DMF.

Table 2.3. Optimization results for on-resin glutaraldehydation.
Modification solution

Glutaraldehydated:unmodified

141:70:141:49:48 (Gl/THF/MeOH/PyB/NMM), O/N, RT

16:1

141:70:141:49:48 (Gl/THF/MeOH/PyB/NMM), )/N, 37°C

36:1

141:70:141:49:26 (Gl/THF/MeOH/PyB/HOAc), O/N, RT

2973:1

141:141:70:49:48 (Gl/THF/MeOH/PyB/NMM), O/N, RT

203:1

2.3. Preparation of peptidyl reagent activated esters and derivatization of standard peptide
mixtures

2.3.1. Experimental

2.3.1.1. Research Facilities

All sample preparations are performed in a Biosafety Level 2 laboratory within the
Department of Chemistry (R409 and R411, Xudong Yao Lab, Chemistry Building). LC-TOFMS will be performed using 10ADvp system (Shimadzu, Kyoto) and quadrupole time-of-flight
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(QTOF) mass spectrometer (QSTAR Elite, Applied Biosystems), located in the MS facility of
the Department of Chemistry (R403).

2.3.1.2. Materials and reagents

Dimethylacetamide (DMAc), LC-MS grade acetonitrile (ACN), 4-(4,6-Dimethoxy-1,3,5triazin-2-yl)-4-methylmorpholinium chloride (DMTMM), N-Methylmorpholine (NMM), and
1,4-Dimethylpiperazine (DMPipZ) were purchased from Sigma-Aldrich (St. Louis, MO).
Trifluoroacetic acid (TFA) and formic acid (FA) purchased from Fisher (Pittsburgh, PA).
Standard synthetic peptides were from Peptide 2.0 (Chantilly, VA), AnaSpec (Fremont, CA), and
Thermo Fisher (Pittsburgh, PA). Direct-Q3 water system (Millipore, Billerica, MA) was used to
purify deionized water. Samples were dried using SpeedVac (Savant, Farmingdale, NY), vacuum
oven (Fisher Scientific, Pittsburgh, PA) or lyophilizer (Labconco, Kansas City, MO). Incubation
of samples was performed on Hula Mixer (Invitrogen, Grand Island, NY) or Thermomixer R
(Eppendorf, Hauppauge, NY).

2.3.1.3. Derivatization of standard peptides using peptidyl reagent sets

Activated peptidyl reagent was prepared by adding 1 µmol/11 µL DMTMM in DMAc, 9
µL of NMM:DMAc [1:80 (v/v)] and 20 µL DMAc in a tube containing dried aliquot of 2.5 µmol
peptidyl reagent. The resulting solution was incubated for 1 hr at room temperature.
Immediately, 30 µL of the activated reagent was transferred into another tube with 5 µL of
DMPipZ:DMAc [1:10 (v/v)]. A 12 µL aliquot from the resulting solution was added to the
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lyophilized standard peptide aliquot. The standard peptide mixture contained 1 nmol each of
CFTR signature peptide CFTR01 and PSA signature peptides SVI, HSQ, and LSE. In addition to
signature peptides, the standard mixture consisted of synthetic peptides YGGFLR, LSEAVTLK,
IVGGWEK, NSILTETLR, HSTETLR, and SVIGGR. The sample was incubated overnight at
room temperature. The reaction was then quenched with 12 µL of ice-cooled 20% FA for 30 min
and diluted to 75 µL with H2O. A 5 µL aliquot was transferred into another tube containing 85
µL H2O, 5 µL SVI*, and 5 µL HSQ* IS solutions. The samples were then analyzed using LCTOF-MS and LC-MRM-MS.

LC-TOF-MS was performed using 10ADvp system (Shimadzu, Columbia, MD) and
quadrupole time-of-flight (QTOF) mass spectrometers (QSTAR Elite, Applied Biosystems,
Foster City, CA) and QTOFmicro, Waters, Milford, MA). The mobile phase binary gradient
system had solvent A of FA:ACN:H2O [2:10:988 (v/v/v)] and solvent B of FA:H2O, ACN
[2:10:988 (v/v/v)]. LC separation was performed with reversed-phase column (Hypersil GOLD,
1.9 μm, 100 x 1.0 mm, Thermo Scientific, Waltham, MA) set at 60 °C, with flow rate of 80
µL/min. The chromatographic gradient was run with 2% B at 0 min → 60% B at 20 min → 80%
B at 23 min → 80% B at 26 min → 5% B at 27 min → 5% B at 30 min. Key MS instrument
parameters were set at IS 5500 V, GS1 20, CUR 20, DP 30, DP2 15, FP 280, CAD 10, and m/z
range 300-1500. LC-MRM-MS was performed using the 10ADvp system described above and
4000 QTRAP triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA).
Similar chromatographic parameters were employed. Key MRM MS instrument parameters were
set at IS 4000 V, GS130, CUR 20, IHT 150, EP 10, and CXP 10.
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2.3.2. Results and discussion

2.3.2.1. In-situ activation and derivatization scheme

The reagent libraries were screened to develop reagents that could enhance the MS
detection of SVI and CFTR01. Since >95% chemical conversion is the target chemical
conversion yield for the peptide derivatization in this work, selection of peptidyl reagents and
derivatization conditions were optimized. When conversion yield of 44% for short peptide
YGGFLR derivatizations was obtained with DMTMM as the activating reagent, the labeling
method was further optimized and applied to CFTR01 and PSA model peptides. In experiments
with single peptidyl reagent (Ac-AFL-OH), the optimum condition for CFTR01 derivatization
was with DMTMM and PyBOP as activating reagents, both with >98% conversion yield for AcAFL-NSILTETLHR product. Peptide samples were then derivatized following in-situ activation
via formation of activated triazine esters of peptidyl reagents with DMTMM (Scheme 1). Figure
2.3 contrasts the structure of a peptidyl reagent, Ac-AFL, with mTRAQ reagents in Figure 1.3

Peptide mixture samples of CFTR01 (1 nmol) and SVI (1 nmol), together with eight
other synthetic peptides constituting a total of 20 nmol of peptidyl amine groups, were
derivatized with 2.5 µmol (theoretical) of each of the reagent mixtures. Figure 2.4 shows TOFMS/MS of CFTR01 derivatized by peptidyl reagents Ac-AFL and Dim-βAAFL.
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a

b

Scheme 1. DMTMM-mediated derivatization scheme (a) DMTMM-mediated activation of
peptidyl reagent, Ac-AFL-OH; (b) followed by derivatization of Peptide CFTR01.

Ac-AFL

Ac-AFL activated

Figure 2.3. Structures of peptidyl reagent Ac-AFL (acetylated) and activated Ac-AFL.
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Figure 2.4. (a) LC-TOF-MS/MS spectrum of Ac-AFL-NSILTETLHR (CFTR01 derivatized
with acetylated AFL (Ac-AFL), m/z 778.93 for doubly charged precursor ions). The reaction is a
typical passive derivatization giving multiple derivatized b-ions and corresponding y-ions. (b)
LC-TOF-MS/MS spectrum of Dim-βAAFL-NSILTETLHR (CFTR01 derivatized with
dimethylated βAAFL (Dim-βAAFL), m/z 778.93 for doubly charged precursor ions).

Both TOF-MS and MRM MS modes are used for screening. TOF MS screening was
mainly for the ease of batch analysis. Eventually, however, MRM will be the mode of analysis
for actual biological samples. MRM transition [M+2H]  y5 for peptide SVI derivatized by AcAFL is shown in Figure 2.5.
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Figure 2.5. Representative MRM transition structure of a doubly-charged derivatized precursor
fragmenting to y5.

2.3.2.2. Calculating percentage of chemical conversion and signal yield for mass
spectrometry

The extent of derivatization efficiency was determined by two quantitative parameters:
(1) percentage of chemical conversion (PCC); and (2) signal yield for mass spectrometry
(SYMS). PCC and SYMS were calculated for each peptide derivatization using Equations 1 and
2, where Int 1 = PA or PH of underivatized peptide; Int 2 = PA or PH of labeled peptide; Int 3 =
PA or PH of derivatized peptide; and R = concentration ratio of peptide to spiked labeled
peptide. Quantitative criteria were then set at >90% PCC and >100% SYMS for a peptidyl
reagent to pass derivatization screening.

𝑃𝐶𝐶 =

(𝐼𝑛𝑡 2 × 𝑅)−𝐼𝑛𝑡 1

𝑆𝑌𝑀𝑆 =

𝐼𝑛𝑡 2 × 𝑅

𝐼𝑛𝑡 3
𝐼𝑛𝑡 2 × 𝑅

× 100%

× 100%

Eq. 1

Eq. 2
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These two criteria were set to ensure that not only a reagent could effectively derivatize
peptides (measured by PCC), but also importantly, the added steps of sample derivatization and
cleanup did not lead to a detectability loss (measured by SYMS). After identifying reagents that
yield suitable derivatizations, the procedure was then be adapted to develop a robust method for
the analysis of the model protein biomarker in the study. The reagents were then individually
synthesized on a larger scale and purified in an LC-UV system.

2.3.2.3 Selection of activating reagent and reaction conditions

Initially, to achieve optimum conditions, a number of activation schemes were employed
and the resulting derivatization efficiencies were compared. Several activating compounds such
as ethylene dichloride/N-hydroxysuccinimide (EDC/NHS), diisopropyl carbodiimide/Nhydroxysuccinimide

(DIC/NHS),

benzotriazol-1-yl-oxytripyrrolidinophosphonium

hexafluorophosphate (PyBOP), and DMTMM were used to activate peptidyl reagent Ac-AFLOH. Activated Ac-AFL-triazine ester was then added to signature peptide CFTR01 at pH >8.0
with bases DMP and triethylammonium bicarbonate buffer pH 8.0 (TEAB). Results from the use
of different activating reagents and bases are summarized in Table 2.4.

Extraction of activated reagent ester with DCM/H2O, which could remove unreacted
compounds, resulted to lower SYMS (less than 10%). In this method, DMTMM and NMM were
added in excess, followed by immediate extraction of unreacted reagents. The activated peptidyl
reagent ester, retained in DCM layer, was then dried down in SpeedVac and reconstituted in.
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DMAc. Different solvents used for derivatization with resulting PCC and SYMS are shown in
Table 2.5, wherein DMAc appears to be the best solvent.

Table 2.4. Various activating reagents and bases and their effect on PCC and SYMS.
Base used in derivatization reaction
Activating

DMP

reagents

TEAB

PCC, %

SYMS, %

PCC, %

SYMS, %

NHS/EDC

12.6

N/D

5.1

5.2

NHS/DIC

<1

N/D

<1

N/D

PyBOP

97.7

54.9

72.2

N/D

DMTMM

99.9

378.5

83.4

33.0

Table 2.5. Derivatization reaction solvents and their effects on PCC and SYMS.
Ac-AFLNSILTETLHR

DMAc

1/10

1/10 dilution,

dilution,

20% n-PrOH/

DMAc

DMAc

20%

5%

n-PrOH/ DMAc

DIEA

DMF

PCC, %

92

18

90

96

43

87

SYMS, %

117

36

7

15

23

75

Upon formation of peptidyl reagent triazine ester after 1 hour, it was found that overnight
reaction incubation was sufficient for obtaining PCC of >90%. Figure 2.6 illustrates increase in
PCC observed with increasing derivatization time. Other optimization measures, listed in Table
2.6, such as addition of HOBT, increased temperature, and quenching with hydroxylamine did
not yield to significant signal increase.
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Table 2.6. Relative signal enhancement effects of varied reaction conditions.
Optimization

Relative SYMS

36 h reaction

0.7

60 h reaction

0.1

Higher temperature (37°C)

0.8

Extracted with DCM/ H2O

0.1

NH2OH-Quenched

1.0

100

PCC (%)

80
60
40
20
0
0

5

10

15

20

25

Reaction time (hr)

Figure 2.6. Time-course reaction dynamics for DMTMM-mediated derivatization of CFTR01
with Ac-AFL.
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2.3.2.4. Signal enhancement for proteotypic signature peptides of model biomarkers

Passing reagents had varying residue sequences and capping groups. They produced a
wide range of SYMS values for the derivatized peptides, up to 100-fold for CFTR01 and 50-fold
for SVI. Complete screening list is provided in the Appendix. To investigate if there is a
structural determinant controlling the MS signal enhancement, SYMS values for derivatized SVI
peptides were plotted against their aliphatic index (AI) values (the acetyl capping group on the
derivatizing reagents was not included in the AI calculation) and grand average of hydropathicity
(GRAVY).

AI is the relative volume of the aliphatic side chains of a protein. The calculation
accounts for the amount of aliphatic side chains, namely alanine, valine, isoleucine, and leucine.
The capping groups were not accounted for; the calculated values include the SVI sequence and
derivatizing

peptidyl

sequence.

Obtained

from

the

Expasy

site

(http://web.expasy.org/protparam/protparam-doc.html), the equation for obtaining the aliphatic
index (AI) is given by Equation 3:

𝐴𝐼 = X(𝐴𝑙𝑎) + 2.9 ∗ X(𝑉𝑎𝑙) + 3.9 ∗ (X(𝐼𝑙𝑒) + X(𝐿𝑒𝑢))

Eq. 3

Where X is the mole percent of each aliphatic residue, a is the coefficient of the relative
volume of valine equal to 2.9, and b is the coefficient of the relative volume of isoleucine/leucine
equal to 3.9. On the other hand, GRAVY is equivalent to the sum of the hydropathy values of all
the amino acids in a protein or peptide sequence divided by the number of the residues, given in
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Equation 4. The values are obtained from the amino acid hydropathicity scale values from Table
2.7.24
𝐺𝑅𝐴𝑉𝑌 =

∑H𝑛
𝑛

Eq. 4

Table 2.7. Amino acid hydropathicity values for calculating GRAVY (adapted from Kyte and
Doolittle, 1982).
Amino acid

Scale value

Ala

1.800

Arg

-4.500

Asn

-3.500

Asp

-3.500

Cys

2.500

Gln

-3.500

Glu

-3.500

Gly

-0.400

His

-3.200

Ile

4.500

Leu

3.800

Lys

-3.900

Met

1.900

Phe

2.800

Pro

-1.600

Ser

-0.800

Thr

-0.700

Trp

-0.900

Tyr

-1.300

Val

4.200
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A general decrease in SYMS was observed with the AI and GRAVY increase for
acetylation. However, a similar effect was not apparent with reagents capped with a dimethyl
group. Figure 2.7 compares the SYMS with the varying peptide properties. Dimethylated
reagents were generally among the compounds with higher SYMS values. Among successful
reagents derivatizing SVI (180 reagent candidates) and CFTR01 (102 reagent candidates), a
common preference on the residue sequence of reagents was not observable for the MS signal
enhancement, as shown in Figure 2.8. Conversion to derivatized product and signal enhancement
are also assessed for the other signature peptides. Poor reproducibility and low PCC for
HSQPWQVLVASK was generally observed. Low detection signals for LSEPAELTDAVK and
IVGGWECEK were also observed. Figure 2.9 compares the SYMS obtained from SVI and
CFTR01 derivatizations with common reagents, signifying peptide-specificity of the reaction.
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Figure 2.7. Plots of SYMS against GRAVY (Grand Average of Hydropathicity) and AI
(Aliphatic Index). A decrease in SYMS was observed with increasing GRAVY and Aliphatic
Index values for reagents with acetyl capping group (Ac), but no trend was apparent with
reagents having dimethyl capping group (Dim).

Figure 2.8. Different N-terminal capping groups of peptidyl reagents and their effect on SYMS.
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Figure 2.9. SYMS of common peptidyl reagents screened for signature peptides CFTR01 and
SVI. Mixtures of peptidyl reagents were prepared via combinatorial split-and-pool method and
screened to evaluate derivatization effects with CFTR01 and SVI.
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Chapter 3. Ultrathroughput mass spectrometry for the N-in-1 quantitation of prostate
specific antigen in human serum samples

3.1. Introduction

The signal enhancement information obtained from screening the peptidyl reagent library
provided important perspectives on the workflow design of targeted protein biomarker
quantitation in multiple samples. The key technological feature is the use of structurally diverse,
non-isotopic reagents to provide the needed sample-throughput potential for ultrathroughput
mass spectrometry (uMS) quantitation of surrogate peptides. We reported a particular
demonstration for quantifying prostate specific antigen (PSA) in multiple serum samples; this
particular workflow is termed as ultrathroughput MRM MS (uMRM MS).1 The use of
“ultrathroughput” was introduced to distinguish uMRM MS from existing strategies that increase
the sample throughput via speeding the analysis of each sample. The new technology provides a
potential economical path to surpass the current sample-throughput potential afforded by isotopic
reagents, transforming the standard MRM technique into a high sample-throughput (N-in-1)
technology for biomarker applications. In contrast to isotopic reagents that exploit the principle
of integrated design, the N-in-1 uMS workflow, depicted in Figure 3.1, is signified by separated
quantitation and sample-coding modules.
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Figure 3.1. N-in-1 uMRM MS workflow illustrating the quantitation and sample coding modular
separation.

Firstly, we separate the quantitation and sample-coding principles to highlight the
economic advantages of the method. In the technology of uMRM MS, the quantitation reference
is the isotopically labeled counterpart of a surrogate peptide target; samples are spiked with a
common quantitation reference that carries stable isotopes. It is important to note that the
isotopic quantitation reference is added only at comparable concentrations (e.g., at the
equivalence to picograms or low nanograms of proteins per milliliter; a minute cost concern)
with those of the endogenous peptide surrogate. Thus, only low amounts of isotopic quantitation
reference (and thus decreased use of expensive stable isotopes) are needed, making the approach
highly cost-effective. If stable isotopes were added to the samples through peptide derivatization,
the quantity of isotopes used would be many orders of magnitude higher, considering that high
abundance proteins (and thus their resulting peptides) are many orders of magnitude higher in
moles2 and these peptides also consume the expensive reagents. In this study, the unique peptide
SVILLGR, denoted as SVI, is the quantitation surrogate for model biomarker PSA. An
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isotopically labeled counterpart, denoted as SVI* (SVIL[L-13C615N]GR), was custom-made as
the common quantitation reference (Scheme 1b). Relative to the frequently used PSA surrogate,
peptide LSEPAELTDAVK,3,4 the MS signal of SVILLGR was found to be about 40%.

The second advantage is the use of inexpensive, non-isotopic reagents for sample-specific
mass coding to improve the sample throughput. This removes the cost barrier involved in using
integrated, isotopic reagents for proteomic quantitation. Further cost savings can be realized
when serum samples of large volumes (e.g., 100 μL) are analyzed. To compete with highly
sensitive immunoassays,5,6 the use of relatively large amounts of samples for quantitation with
yet-to-be-more-sensitive MS instruments currently is a practical solution. For instance, if serum
volume was increased from 10 μL to 100 μL, then the limit of quantitation could be increased by
a maximal factor of 10. However, it is not economically feasible to use stable isotopic reagents to
derivatize peptides from large volumes of sera. Total protein content in 100 μL of serum is
around 8 mg, and their peptides would use tens of milligrams of reagents. A commercial set of
isotopic reagents with six labeling states and 4 mg for each reagent can cost over $2,500 (as of
May 2015); each is only sufficient for derivatizing peptides from 10 μL of non-depleted serum.

The third advantage is the open-source development of chemicals for derivatizing
peptides to achieve enhanced MS detection. Without the need for considering stable isotopes in
the reagent design, the door to utilizing the chemical diversity is left wide open. Virtually any
non-isotopic, reactive chemical becomes a potential candidate for derivatizing peptides and the
selection of a particular chemistry structure is at the user’s choice. Many criteria can be used for
the reagent selection, such as ease of synthesis, scalability, or commercial availability. The most
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significant criterion, however, is the capability of a reagent to improve the MS quantitation limit
for a target peptide.

While peptides cannot be amplified like nucleic acids via the polymerase chain reaction,
that chemical derivatization of peptides can increase MS signals of the molecules has long been
recognized.7-9 The practical utilization of this signal enhancement strategy, however, has been
limited by costly synthesis of stable isotopic versions of signal-enhancing reagents. This is a
disadvantageous consequence of the integrated reagent design. The use of reagent isotopologues
for peptide derivatization is the current practice in MS-based quantitative proteomics. Nonisotopic reagents have been excluded so far, because different reagents have different separation
and MS ionization properties which thus prevent accurate quantitation.

3.2. N-in-1 quantitation of model cancer biomarker prostate specific antigen in serum

3.2.1. Experimental

3.2.1.1. Research facilities

All sample preparations were performed in a Biosafety Level 2 laboratory within the
Department of Chemistry (R409 and R411, Xudong Yao Lab, Chemistry Building). The HPLCUV system (Shimadzu) used for the peptidyl reagent purification is located in R409. LC-TOFMS will be performed using 10ADvp system (Shimadzu) and quadrupole time-of-flight (QTOF)
mass spectrometer (QSTAR Elite, Applied Biosystems). LC-MRM-MS analysis was performed
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using the 10ADvp system described above and 4000 QTRAP triple quadrupole mass
spectrometer (Applied Biosystems). The mass spectrometers are in the MS facility of the
Department of Chemistry (R403).

3.2.1.2. Materials and reagents

Methanol (MeOH), dimethylacetamide (DMAc), LC-MS grade acetonitrile (ACN), urea,
iodoacetamide (IAA), 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride
(DMTMM), N-Methylmorpholine (NMM), 1,4-Dimethylpiperazine (DMPipZ), CHAPS (3-((3Cholamidopropyl)dimethylammonio)-1-propanesulfonate hydrate), boric acid, sodium phosphate
monobasic monohydrate, sodium phosphate dibasic dehydrate, acetic acid and dimethyl
pimelimidate (DMP) were purchased from Sigma-Aldrich (St. Louis, MO). Trifluoroacetic acid
(TFA), formic acid (FA), sodium hydroxide, and DL-Dithiothreitol (DTT) were purchased from
Fisher (Pittsburgh, PA).

Standard synthetic peptides were from Peptide 2.0 (Chantilly, VA), AnaSpec (Fremont,
CA), and Thermo Fisher (Pittsburgh, PA). Female serum was from BioChemed (Winchester,
VA). Human prostate specific antigen was purchased from Lee Biosolutions (St. Louis, MO).
Sequence-grade trypsin was purchased from Roche (Indianapolis, IN). Standard synthetic
peptides were from Peptide 2.0 (Chantilly, VA), AnaSpec (Fremont, CA), and Thermo Fisher
(Pittsburgh, PA). Anti-SVI antibody CON-1 was developed and purchased from Epitomics
(Burlingame, CA). Dynabeads Protein G and Phosphate Buffered Saline (PBS) 10X Solution pH
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7.4 were from Life Technologies (Grand Island, NY). Dynal-MPC-S magnetic particle
concentrator was obtained from Invitrogen (Oslo, Norway).

Direct-Q3 water system (Millipore, Billerica, MA) was used to purify deionized (DI)
water. Samples were dried using SpeedVac (Savant, Farmingdale, NY), vacuum oven (Fisher
Scientific, Pittsburgh, PA) or lyophilizer (Labconco, Kansas City, MO). Incubation of samples
was performed on Hula Mixer (Invitrogen, Grand Island, NY) or Thermomixer R (Eppendorf,
Hauppauge, NY).

3.2.1.3. Tryptic digestion of prostate specific antigen and spiked serum

To 100 μg of sample (protein in NH4OAc buffer or pure serum) , 8M urea in 100 mM
NH4OAc pH 8.0 buffer (100 μL) was added and the tube was vortexed for 30 sec. Additional 100
μL of NH4OAc pH 8.0 buffer was added to dilute the sample. Reduction was carried out by
adding 4 μL of 500 mM DTE for 30 min at 30°C and let to cool down, followed by alkylation
with 15 μL of 500 mM IAA for 30 min at RT in the dark. Further dilution with NH4OAc pH 8.0
buffer to a total urea concentration of 2 M was performed prior to digestion. Trypsin was added
to the sample, with an enzyme-substrate ratio of 1:25. The sample was incubated overnight at
37°C. To quench the reaction, 10% TFA was added (total TFA concentration of 2%, v/v) and
incubated for 10 min. The resulting digests were subsequently desalted using Oasis HLB
(hydrophilic-lipophilic balance) material, lyophilized, and stored at -20°C.
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3.2.1.4. Sample cleanup by desalting

The sample was ensured to have a pH of less than 3 by adding 20% FA. About 100 µL of
HLB bulk material beads in ACN suspension was packed in an empty toptip. The beads are
conditioned with (5 × 200 μL) ACN, drained manually using a plunger. Air bubbles are taken out
using a narrow pipette tip and the beads are kept wet throughout the desalting process. The beads
were further equilibrated with (3 × 200 μL) 5% (v/v) ACN + 95% (v/v) (0.1%, v/v of TFA in DI
water). The sample was loaded to the equilibrated HLB beads, collecting the flow-through. The
flow-through was reloaded and drained. The sample-containing beads were washed with (3 ×
200 μL) 0.1% (v/v) TFA, collecting the wash with the flow-through. Using a clean new tube for
collection, 200 µL of 70% (v/v) ACN was used for eluting the bound peptides. The eluent was
dried in the SpeedVac to remove organic solvent and subsequently lyophilized. The beads could
be washed with 70% (v/v) ACN and left suspended in ACN for future reuse.

3.2.1.5. Sample-specific derivatization of digests

Each sample was assigned unique peptidyl reagent for sample-specific derivatization.
The activated reagent was prepared by adding 1 µmol/11 µL DMTMM in DMAc, 9 µL of
NMM:DMAc [1:80 (v/v)] and 20 µL DMAc in a tube containing dried aliquot of 2.5 µmol
peptidyl reagent. The resulting solution was incubated for 1 hr at RT. Immediately, 8 µL of
DMPipZ:DMAc [1:10 (v/v)] was added into each activated reagent and mixed. The activated
peptidyl reagent solution was then added to the lyophilized digest and incubated overnight at RT.
The reaction was then quenched with 58 µL of ice-cooled 20% FA for 30 min and concentrated
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using speed vac (about 30 min) to dry out organic solvents. Each sample was then diluted to 1.5
mL with H2O and subsequently desalted (Section 3.2.1.4), this time using 1 mL loads in 1 cc
HLB cartridge set in vacuum manifold. Eluted samples were combined and concentrated using
SpeedVac and lyophilizer, until the total volume is about 300 µL. Single peptide enrichment was
performed (as below) on the pooled sample using 0.75 mg beads. The sample was reconstituted
using 0.1% TFA and incubated at RT for 30 min. Finally, the sample was centrifuged at 13.2
rpm for 30 min at 4°C, and analyzed in NanoLC-MRM MS.

3.2.1.6. Immunoenrichment of derivatized signature and internal standard peptide SVI

3.2.1.6.1. Immobilization of antipeptide antibody against peptide SVI

Buffers and solutions. The following buffers were prepared for the immunoenrichment
protocol. CHAPS Buffer (0.03% CHAPS in 1X PBS) was prepared from a solution of 1X PBS
solution pH 7.4 from (10X stock) and used to dilute 0.03% CHAPS (v/v). Buffer A (0.1 M
borated buffer pH 9.5) was prepared by dissolving 6.18 g boric acid in 800 mL DI water,
adjusting the pH to 9.5 using 5 M sodium hydroxide, and finally diluting the solution to 1 L with
DI water. Buffer B (0.1 M sodium phosphate buffer, pH 7.4) was prepared by dissolving 2.62 g
sodium phosphate monobasic monohydrate and 14.42 g sodium phosphate dibasic dihydrate, the
pH was checked to be 7.4, followed by diluting the solution to 1 L with DI water.

Washing. A vial of Dynabeads Protein G was vortexed and centrifuged in high speed.
The beads were then re-suspended by vortexing the vial in lower speed for >30 s. Four aliquots
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of 50 μL (equivalent to 1.5 mg) were prepared. The beads were centrifuged for 3 s and placed on
the magnet for 1 min to allow time to settle before removing the supernatant. To each tube,
immediately, 200 μL of CHAPS Buffer was added, vortexed, and then centrifuged. The
supernatant was removed to discard. This washing step was performed twice. Another 200 μL
was added to re-suspend the beads, which were all pipetted out and transferred to a new tube.
This was followed by washing the tubes with 50 μL of CHAPS Buffer, adding the wash to the
new tube. The tubes were placed on the magnet for 1 min and the supernatant was removed to
discard.

Binding of antibody. Four tubes containing 10 μg (24 μL) of CON-1 Antibody for SVI
(kept at -20 ˚C) diluted to 200 μL with CHAPS Buffer were prepared. Gentle pipetting was
performed to mix the solution thoroughly to avoid generating bubbles. The antibody solutions
were then transferred respectively to the tubes containing the beads, followed by washing with
50 μL of CHAPS Buffer, adding the wash. The tubes were flicked to re-suspend the beads,
sealed, and incubated in a HulaMixer for 30 min. For incubation, the HulaMixer had the
following parameters: orbital 45 rpm (1 s), reciprocal 35° (5 s), and vibro/pause 1° (2 s). The
tubes were centrifuged and placed on the magnet. The supernatant was then removed and kept.
To wash the beads, 200 μL of CHAPS buffer was added to each tube. The tubes were flicked to
re-suspend the beads and incubated at RT for 3 min. For incubation, the HulaMixer had the
following parameters: orbital 45 rpm (2 s), reciprocal 35° (5 s), and vibro/pause 1° (3 s). The
tubes were centrifuged, placed on the magnet, and the supernatant was collected to keep. The
washing step was performed for two more times, discarding the supernatant.

60

Crosslinking. To each tube, 200 μL of Buffer A was added. The tubes were flicked to resuspend the beads, centrifuged, and while on the magnet removed of supernatant to be kept. The
washing step was repeated once, discarding the supernatant. A 100 μL solution of Buffer A was
then added to each tube. Meanwhile, the crosslinking solution was prepared freshly (10 mM
DMP in 100 mM Borate Buffer) by dissolving 5.2 mg of DMP with 1600 μL of Buffer A. For
each tube containing the beads and 100 μL Buffer A, a 400 μL aliquot of the crosslinking
solution was added. Each tube was flicked, sealed with parafilm, and covered with foil. The
tubes were then incubated at RT for 30 min in dark. For incubation, the HulaMixer had the
following parameters: orbital 45 rpm (1 s), reciprocal 35° (3 s), and vibro/pause 1° (3 s). The
tubes were centrifuged, placed on the magnet, and the supernatant was removed and discarded.

Quenching. Briefly, the reaction was stopped by adding 500 μL of 50 mM Quenching
Buffer (Tris pH 7.5). Each tube was flicked, sealed, and incubated at RT for 15 min with the
following HulaMixer parameters: orbital 45 rpm (1 s), reciprocal 35° (3 s), and vibro/pause 1° (3
s). The tubes were centrifuged, placed on the magnet, and the supernatant was removed and kept.
To wash the beads, a 500 μL solution of Buffer B was added. Each tube was flicked and
incubated at RT for 3 min with the following HulaMixer parameters: orbital 45 rpm (2 s),
reciprocal 30° (5 s), and vibro/pause 1° (3 s). The tubes were centrifuged, placed on the magnet,
and the supernatant was collected to keep. The washing step was performed for two more times
using CHAPS Buffer, discarding the supernatant.

Acid wash was then carried out to remove antibodies that were not cross-linked to the
beads. To each tube, 200 μL of Acid Wash Buffer was added. The tubes were then flicked and
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incubated at RT for 2 min with the following HulaMixer parameters: orbital 45 rpm (2 s),
reciprocal 45° (5 s), and vibro/pause 1° (3 s). The tubes were centrifuged, placed on the magnet,
and the supernatant was removed and kept. To wash the beads, a 500 μL solution of Buffer B
was added. Each tube was flicked and incubated at RT for 3 min with the following HulaMixer
parameters: orbital 45 rpm (2 s), reciprocal 35° (5 s), and vibro/pause 1° (3 s). The tubes were
centrifuged, placed on the magnet, and the supernatant was collected to keep. The pH of the
supernatant was measured. The washing step was performed for two more times using CHAPS
Buffer, discarding the supernatant. Lastly, 150 μL of CHAPS Buffer was added to each tube. The
suspension was pipetted gently and all beads were transferred to one new tube and mixed
thoroughly. Additional 50 μL was used to wash each previous tube, collecting all washings to the
new one. After mixing my repeated pipetting, 16 aliquots of 50 μL were prepared. Each tube
then contained 0.375 mg beads and stored in the fridge.

3.2.1.6.2. Immuno-affinity pulldown procedure

Washing. The digest sample was ensured to have a pH of 8 (using PBS buffer-2%
MeOH (v/v)). Meanwhile, an aliquot of beads with immobilized antibodies (0.375 mg) were
centrifuged and placed on the magnet. The supernatant was removed to discard. The peptide
solution was transferred to the tube containing the beads with immobilized antibodies, using
additional 50 μL of CHAPS Buffer to wash the tube that contained the sample. The tube was
flicked and incubated at RT for 2 hrs with the following HulaMixer parameters: orbital 45 rpm (1
s), reciprocal 35° (5 s), and vibro/pause 1° (2 s). The tube was centrifuged, placed on the magnet,
and the supernatant was removed and kept. To wash the beads, a 200 μL solution of CHAPS
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Buffer was added. Each tube was flicked and incubated at RT for 3 min with the following
HulaMixer parameters: orbital 45 rpm (2 s), reciprocal 35° (5 s), and vibro/pause 1° (2 s). The
tubes were centrifuged, placed on the magnet, and the supernatant was collected to keep. The
washing step was performed for two more times, discarding the supernatant.

Elution. Immediately, a 200 μL solution of Elution Ready Buffer (20 mM NH4HCO3)
was added to the tube. Using a wide-mouth pipette tip, the beads are re-suspended and
transferred to a new clean tube to prepare for elution. While on the magnet, the supernatant was
taken out to clean the previous tube, aiding in transferring the rest of the suspension. The
washing step was repeated once, the tube was centrifuged, and the supernatant was discarded. To
elute, 30 μL of Elution Buffer was added to the tube. The tube was flicked and incubated at RT
for 2 min with the following HulaMixer parameters: orbital 45 rpm (2 s), reciprocal 35° (5 s),
and vibro/pause 1° (2 s). The tube was centrifuged, placed on the magnet, and the supernatant
was collected into a new tube. The elution step was repeated with 30 μL of Elution Buffer.
Immediately, 150 μL of DI water was added to the eluent. The solution was vortexed and
subsequently centrifuged using Centrifuge 5415 R at 16.1×103 rcf, 4˚C for 30 min. Afterwards,
the tube was placed in the magnet and the solution was transferred to a new clean tube and
lyophilized for storage (-20˚C) and MS analysis.

Meanwhile, the beads are washed three time using 200 μL of Buffer E, incubating for 3
min at RT with the following HulaMixer parameters: orbital 45 rpm (2 s), reciprocal 35° (5 s),
and vibro/pause 1° (2 s). All the wash solutions are discarded. After the final wash, 50 μL of
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CHAPS Buffer was added to transfer the suspension to a new tube, for storage. The used
immobilized antibody suspension was kept at 4˚C.

3.2.2. Results and discussion

3.2.2.1. The methodology of modular N-in-1 uMRM protein biomarker quantitation

Prostate-specific antigen (PSA), a 29-kDa protein, is the primary biomarker for prostate
cancer and has a reported limit of quantitation of 1 ng/mL in serum.10,11 Clinically, a healthy
serum contains <4 ng/mL PSA. Herein, PSA peptide SVILLGR (SVI) is selected as the signature
peptide for uMRM measurements of the protein. Non-depleted female serum samples (analyzed
for zero PSA content) were spiked with PSA, enzymatically digested using trypsin, spiked with
SVILL*GR (SVI*), and derivatized with in-house synthesized peptidyl reagents in a samplespecific manner. Trypsin is a protease that cleaves on arginine and lysine residues. The protein
content of the commercially-obtained female serum was analyzed in Qubit fluorometer using
Quant-iT protein assay kit, and found to be about 80 mg/mL. Figure 3.2 shows the methodology
of the modular design of N-in-1 uMRM quantitation.

MRM predicted transitions and peak area quantitation were analyzed using Skyline
software. The following analytical figures of merit were the criteria for the robustness and
reproducibility of the method: (1) validation of accuracy and reproducibility (<20% error with
<20% CV) of the qualified peptide derivatizations; and (2) determination of limit of quantitation
and dynamic range.

64

Figure 3.2. Procedure for the quantitation of PSA in multiple serum samples. After samplespecific derivatizations, the samples will be pooled, processed, and quantified (PSA) in a single
analysis.

3.2.2.2.

Mitigating

the

sample

overloading

and

dilution

limitations

through

immunoenrichment

As PSA is among low-abundant proteins in the serum proteome, coupled with the high
complexity of the matrix, reproducibility and MS overloading issues are the major challenges in
the protein quantitation method presented. Analysis of low-abundant proteins in serum typically
employs depletion techniques to eliminate high abundant proteins. Prior depletion of abundant
proteins can be performed to address the overloading issue as well. Initially, a preliminary
depletion experiment was performed, using Albumin/IgG Spin depletion column to strip the
serum with high-abundant proteins and albumins. As expected, higher recovery and sensitivity
was attained in the mass spectrometry analysis. However, this additional upstream sample
processing is not practical when dealing with large number of samples, particularly when the
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method is adapted for validation applications. Considering the number samples in the validation
phase, it is not cost-effective to perform large-scale depletion. Therefore, an alternative
downstream sample treatment is necessary to achieve a collective enrichment of target peptides.

To deal with high sample complexity and to increase the sensitivity of the method,
immunoaffinity enrichment technique for target peptide was performed prior to MRM analysis.
The peptide level enrichment method, adapted from Stable Isotope Standard Capture by
Antipeptide Antibody (SISCAPA), thus alleviates the depletion requirement to detect lowconcentration proteins targets.2 This step mitigates the overloading and dilution limitations in
uMRM strategy applied for one-experiment quantitation of derivatized peptides for protein
biomarker validation. The immuno-enrichment strategy removed non-target peptides and
enriches already derivatized SVI and SVI* from the complex pooled nondepleted serum digest,
illustrated in Figure 3.3. Polyclonal antibody immobilization and crosslinking for the target
peptide pulldown was optimized for anti-SVILLGR, using Protein G Dynabeads. The custom
polyclonal antibody was developed against the C-terminus of peptide SVI (noting that the
peptide derivatization occurs at the N-termini of the peptides).
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Figure 3.3. Sample pooling and immunoenrichment on the peptide level.

Advantages of SISCAPA over immunoassays such as ELISA include lower cost and
higher quality assay in general. In contrast to SISCAPA methods, immunoassays use monoclonal
antibodies with very high analyte specificity, using one antibody reagent for each sample.2,12-14
Therefore, the use of a single antibody reagent in the uMRM workflow is less expensive and
more importantly, simpler. Quantitation with SISCAPA-derived techniques also presented
results of sufficient sensitivity, reproducibility and robustness, analyte structure characterization,
detection of interference, ease of multiplexing, and improved throughput.15 Analytical
parameters for SISCAPA-MRM include (1) selection of proteotypic peptides, (2) selectivity, (3)
limit of quantitation, (4) linear response and recovery, and (5) reproducibility and
transferability.6

Initial efforts on SVI enrichment method development were exerted on standard peptide
mixtures and pure PSA protein digests. Selected reagents from screening phase were individually
synthesized and purified by high performance liquid chromatography. Digests of PSA samples
67

(2, 12, 122, and 184 ng/mL) were derivatized in a sample-specific manner using Pic-GGG, PicGGA, Pr-VGA, and Pr-VLA. The resulting uMRM data for the surrogate SVI was found to be
linear, shown in Figure 3.4. This preliminary 4-in-1 uMRM MS calibration result implicated the
capability of the method to be adapted for the analysis of real clinical samples.

Figure 3.4. Linearity analysis for 4-in-1 uMRM MS of derivatized PSA digests.

3.2.2.3. Recovery and precision (9-in1) analysis

In a validation recovery experiment for 16 reagent candidates, 16 aliquots of 100 µL of
non-depleted sera were spiked with PSA at a concentration of 300 ng/mL and digested by
trypsin. To each of the resulting digests, the same amount (5 pmol, experimentally determined in
order to obtain similar MS signal intensities for both SVI and SVI*) of SVI* was added.
Following the uMRM analysis workflow, 9 reagents resulted in strong MRM signals for the
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derivatized SVI and SVI*. The chromatogram shows overlapping peaks corresponding to SVI
and SVI* derivatized by nine peptidyl reagents listed, where dashed denote SVI while solid
lines, SVI* (isotopic quantitation reference). This experiment was also designed to assess the
quantitation precision for the uMRM workflow. In the derivatization of 9 successful reagents, the
average ratio of CapGr-AAn…AA2AA1-SVI to CapGr-AAn…AA2AA1-SVI* was calculated to
be 1.70 and the coefficient of variation to be 11.5% (Table 3.1). This precision was comparable
to our previous proof-of-concept study (the coefficient of variation was 9.2%) on a simple
protein digest.1

Figure 3.5. Extracted ion chromatogram for quantitation of PSA in non-depleted sera in a 9-in-1
uMRM MS analysis.
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Table 3.1. Peak area ratio values calculated for the relative quantitation of non-depleted serum
samples spiked at 300 ng/mL PSA through 9-in-1 uMRM MS.
Peptidyl
Reagent

Peak Area
Ratio

CV

Pr-VGA

1.58

11.1

Pr-VLA

1.99

10.0

Pr-AFG

1.38

21.7

Pr-AGA

1.52

11.7

Pr-ALA

2.02

12.3

Pic-GLG

1.52

8.09

Pic-GFG

1.88

16.0

Pic-GGA

1.90

6.53

Pic-GGG

1.53

5.56

Average PA Ratio = 1.70
Total CV = 11.5

The high quantitation precision is another advantageous consequence of the modular
design of the uMRM MS technology. The decoupled use of isotopic quantitation references and
peptide mass coding allows for the passage of authentic quantitative information in original
samples.1,16,17 The common quantitation reference SVI* was added before the derivatization
and this practice mitigated quantitation problems associated with quantitative proteomics that are
based on isotopic derivatization of peptides.18 In such a multiplexing experiment, each sample is
separately derivatized with one reagent from a set of isotopologues, which brings in an added
source for variations in accuracy and precision. It is unavoidable to have incomplete
derivatization and side reactions, but the target SVI and the quantitation reference SVI* would
experience the same degree of the derivatization imperfection. Additionally, the uMRM
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technology can also be used in pair with isotopic proteins as quantitation references, which can
further eliminate quantitation variations originated from protein-level sample preparations.19

3.2.2.4. Low concentration (7-in-1) analysis

Another investigation examined the practicality of using reagent candidates for the
uMRM MS quantitation of PSA at concentrations that are clinically relevant.3,11 This
investigation analyzed PSA in 1/10 non-depleted female serum. Seven out of the 14 reagent
candidates successfully quantified equivalents of 600 pg of PSA on column using a 4000
QTRAP (an earlier generation of triple quadrupole mass spectrometers), shown in Figure 3.6.
The experiment was performed by Yuanyuan Shen in support of the study. Inset shows screening
transitions for light and heavy Pr-ALA-SVILLGR in an early phase of reagent screening.

A master stock of dried digest of PSA-spiked female serum, equivalent to the digest of
200 µL of non-deplete serum containing 17 ng of PSA was first prepared and reconstituted with
DMAC, Aliquots were made so that each contained an equivalent of 1 ng PSA with 1/10 (1/11.8
exactly) serum as the background matrix. Fourteen aliquots were used for the experiment and
peptides in each sample were derivatized with a unique reagent. All 14 samples were pooled and
cleaned as described in the experimental section using immobilized antibody reagent. The
cleaned, pooled sample was reconstituted with 10 µL of 0.1% TFA. Due to the limitations of the
sample amount and instrument used, two sets of NanoLC uMRM analysis were run. First, each
derivatized peptide was monitored for two transitions (in total, 56 transitions for all derivatized
SVI and SVI*), to allow for identifying successful peptidyl reagents/derivatizations and best
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transitions. This analysis only monitored 14 transitions in total, which made it possible to
quantify the SVI peptide at an equivalence of 600 pg of PSA on column with a 4000 QTRAP.

Figure 3.6. Extracted ion chromatogram for quantitation of clinically significant amounts of
PSA in non-depleted diluted sera in a 7-in-1 uMRM analysis (credits to Yuanyuan Shen).
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3.2.2.5. LOQ linearity (5-in-1) analysis

To investigate linearity of the developed method at low, clinically significant concentration in
serum, a 5-in-1 linearity analysis was performed. A single experiment on sample-specific
derivatized SVI-spiked diluted serum digests established a calibration curve for SVI, using 5-in1 uMRM MS analysis. Digests samples containing 1, 2.5, 10, 30, and 60 ng/mL spiked with 8
ng/mL SVI* were derivatized in a sample-specific manner using Dim-FVAA, Dim-GAG, PrLGG, Pr- GFG, Dim-LGF to construct an N-in-1 calibration curve. The analysis resulted to R2
value of 0.9923 (Figure 3.7).

Figure 3.7. Calibration curve for 5-in-1 uMRM analysis of SVI.
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3.2.2.6. Quantitation validation (15-in-1) analysis

To validate the quantitation with higher number of samples on clinical concentration
range, a 15-in-1 uMRM MS analysis was performed (Figure 3.8). SVI and SVI* (theoretically
1:1) were spiked at equivalent concentrations of 1 to 60 ng/mL of SVI, which are clinicallyrelevant. The samples were derivatized by the following reagents: Pr-ALA and Pr-ALG (1
ng/mL), Pr-VLGG and Pr-LGG (2.5 ng/mL), Pr-GLGG and Pr-GLV (5 ng/mL), Pr-VLA and PrGGA (7.5 ng/mL), Dim-GLVV and Pr-GFA (10 ng/mL), Dim-FVAA and Pr-GFG (20 ng/mL),
Dim-LGF and Pic-GGG (40 ng/mL), Dim-GAG and Pic-GGA (60 ng/mL). Dim-GLVV
derivatized SVI was not detected. The average ratio of SVI to SVI* was found to be 0.92
(±0.09), while the overall CV was 10.3% for the replicate sample preparations. When plotted, an
R2 of 0.9986 was obtained, wherein two samples for each concentration level were derivatized
by two different peptidyl reagents and averaged. The CV was determined for three replicate
injections of two different reagents and ultimately averaged for all samples. Only one sample
spiked at 10 ng/mL was included in the plot as the other derivatized sample was not detected (the
initial experiment was designed to be 16-in-1 uMS).

Mass spectrometry analysis of serum digests is prone to complex matrix effects. Thus,
the effect of derivatization reagents with different chemical structures on the chromatographic
elution was carefully considered.

A particular pair of derivatized surrogate and reference

peptides co-elute, thus experiencing the same matrix effect for ionization of both of the peptides.
For some reagents wherein multiple peaks were observed in chromatograms, the total peak area
was used for quantitation. The multiple peaks could be attributed to the presence of isomers in
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reagents, which were in-house synthesized at low milligram scales. Nevertheless, this
complication did not prevent accurate quantitation of SVI, because the signal for derivatized SVI
was normalized by the concurrently derivatized reference, SVI*. It is interesting to note that due
to their inherent hydrophobicity differences, derivatized SVI peptides have different retention
times, spreading over the reversed-phase gradient. The elution order for the derivatized peptides
was more or less predictable when retention time calculators were used (Table 3.2). In
comparison, peptides derivatized with isotopic reagents (excluding certain deuterium labeled) of
a given chemical structure co-elute.
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Figure 3.8. Extracted ion chromatogram and linear plot for 15-in-1 uMRM analysis of SVI in
non-depleted diluted sera. (a) Ion chromatograms of derivatized SVI and SVI* at clinically
relevant concentrations. Serum digests were spiked with SVI (1 to 60 ng/mL) to mimic PSA in a
proof-of-concept N-in-1 validation experiment. (b) Low-concentration plot for SVI constructed
by a single, 15-in-1 uMRM MS.
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Table 3.2. Comparison of predicted and actual chromatographic retention times of derivatized
SVI in 15-in-1 uMRM MS. The capping group on the peptidyl reagent was not included in the
prediction. Predicted RT is obtained from http://theorchromo.ru, while hydrophobicity index is
from http://hs2.proteome.ca/ssrcalc-cgi/SSRCalcQ.pl. Where split peaks are specified, the major
peak was considered for the order in actual relative elution (denoted by asterisk).

Reagent

Dim-GAG

Pic-

RT

Hydro-

Predicted

Actual

phobicity

Relative

Relative

Index

Elution

Elution

RT1

RT2

RT3

42.15

12.51

1

1

63.71

-

-

62.98

18.38

2

2

74.75

-

-

Dim-LGF

69.23

19.49

3

3

79.66

-

-

Pr-GGA

42.72

12.78

1

1

71.79*

73.1

-

Pr-GLGG

50.75

15.39

3

2

77.98

-

-

Pr-LGG

49.07

14.57

2

3

80.72

-

-

Pr-GFG

54.09

16.31

5

4

82.96

-

-

Pr-ALG

53.71

15.73

4

5

83.62

-

-

Pr-VLGG

56.12

16.1

6

6

84.07

-

-

Pr-GFA

57.15

16.91

7

7

85.67*

88.64

-

Pr-ALA

56.73

16.4

8

8

86.14*

91.44

-

Pr-GLV

61.23

18.82

9

9

88.91*

95.55

-

Pr-VLA

61.3

17.2

10

10

77.98

91.05*

96.99

Pic-GGG

40.74

12.23

1

1

74.28

-

-

Pic-GGA

42.72

12.78

2

2

76.26*

78.07

-

Dim- Dim-FVAA

Pr-

Predicted

It is important to note the realization of the unique utilities of affinity-based preparation
step when the number of samples is further increased. First is the sample complexity reduction.
While peptide derivatization results to increased chemical complexity, the antibody reagent
maximally removes interfering chemicals (e.g., large molar excess of reagents) from the
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derivatization mixtures. The chemical interference deleterious to MS analysis compromises the
limit of quantitation for derivatization-based quantitative proteomics. Moreover, derivatized nontarget peptides are also removed in the uMRM workflow, similar to affinity-based MRM MS.
Secondly, enrichment of targeted peptides, compensate for the analyte dilution caused by pooling
multiple samples. The uMRM workflow pools N numbers of samples together for a single MS
experiment, which in turn results in N-times dilution of peptide targets. For instance, when the
samples were combined in the 15-in-1 uMRM MS analysis, analytes in each sample were
subsequently diluted by 15 times. The original sample volume ranged from 67 to 4000 μL,
constituting a total volume of about 15 mL. Using a single step of affinity preparation, the
derivatized SVI and SVI* were reconstituted in a final volume of 10 μL; therefore, the
concentration of endogenous SVI for each sample was increased by 6.7 to 400 times.
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Chapter 4. Ultrathroughput mass spectrometry for global quantitative proteomic profiling
through 18O-labeling in combination with peptide derivatization

4.1. Introduction

The accomplishment of Human Genome Project (HGP) provided the foundation to which
the full complexity of the human proteome will be established. The characterized genome map,
along with available transcriptome and proteomic databases, expedited proteomic efforts for
disease expression profiling.1-3 In 2008, the Human Proteome Organization (HUPO) launched
the Human Proteome Project (HPP) to systematically map the human proteome. Currently, a
major component of HPP, chromosome-centric HPP (C-HPP), is in progress. It was aimed to
provide information on “missing proteins” (proteins that lack MS data or antibody detection). CHPP is being complemented by biology- and disease-driven HPP (B/D-HPP), utilizing combined
resources of worldwide proteomics community.1,2

In light of the clinical relevance of human proteomic research, proteomic technologies for
clinical aspects such as disease pathogenesis, drug and vaccine development, and biomarker
discovery can be obtained from serum proteomic profiles.3-5 In particular, the identification of
disease biomarkers in serum rely on powerful instrumentation and accurate bioanalytical
methodologies. The following, however, are the major challenges encountered

in serum

proteomics: (1) pre-analytical issues including collection, storage, and sample processing, (2)
sample complexity due to large dynamic range of protein concentration, (3) high-abundance
proteins in serum, (4) high levels of salts and potentially interfering compounds, (5) biological
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variations, (6) poor reproducibility, (7) clinical trial design pitfalls, and (8) technical limitations.
Key mass spectrometry technological advancements on different analytical perspectives are
recently developed to alleviate these limitations.4,6

Results from global quantitative proteomic profiling studies can provide important
information on the changes within disease-associated proteins. For instance, control and diseased
plasma sample can be processed (including labeling, digestion, fractionation, and trypsin
digestion) and analyzed for liquid chromatography (LC) tandem mass spectrometry (MS). From
tandem MS data, the proteins are identified through database search. The tandem MS mode
analysis used in identifying proteins is called data-dependent acquisition (DDA), where full MS
scan is performed, followed by tandem MS acquisitions for each detected analytes. From
profiling data, differential proteins associated with the disease can be identified, and ultimately
quantified and benchmarked for further studies.7 Such application of shotgun proteomics for
identifying and profiling proteins in biological samples has presented significant advances in
clinically relevant studies. The serum (more broadly as plasma) proteome, which represents
protein expression of a large number of cell types, contains critical pathophysiological
information including tissue leakages that could serve as biomarkers.

To enable quantitation, stable isotope-labeled peptides (13C- and 15N) are typically added
in known amount as spiked-in quantitation reference. Light and heavy peptides are then
monitored and their ratios obtained to determine the amount of the endogenous peptide.
However, when quantitation is intended for the entire proteomic profile, a simple and costeffective approach is essential. The method of

18

O-labeling has proved to be an efficient means
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to generate a global reference standard out of actual biological sample digests. Global
quantitative proteomic profiling through

18

O-labeling combined with tandem MS analysis have

been reported.8-10 As MRM-based targeted quantitation of disease-associated proteins in
biological samples

11-13

are developed, application of the global labeling method coupled to

MRM MS in discovery and verification of candidate biomarkers also demonstrated the utility of
the strategy for large-scale multiplexing.14,15 Recent MRM improvement strategies for optimized
depth and coverage for low concentration proteins (low ng/mL)16, as well as expedited
workflows through automation of transition selection and optimal MS collision energy (CE)
prediction.17,18

4.2. Proteomic profiling and uMRM quantitative analysis

4.2.1. Experimental

4.2.1.1 Research facilities

All sample preparations were performed in a Biosafety Level 2 laboratory within the
Department of Chemistry (R409 and R411, Xudong Yao Lab, Chemistry Building). The HPLCUV system (Shimadzu) used for the peptidyl reagent purification is located in R409. LC-TOFMS will be performed using 10ADvp system (Shimadzu) and quadrupole time-of-flight (QTOF)
mass spectrometer (QSTAR Elite, Applied Biosystems). LC-MRM-MS analysis was performed
using the 10ADvp system described above and 4000 QTRAP triple quadrupole mass
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spectrometer (Applied Biosystems). The mass spectrometers are in the MS facility of the
Department of Chemistry (R403).

4.2.1.2. Materials and reagents

Methanol (MeOH), dimethylacetamide (DMAc), LC-MS grade acetonitrile (ACN), urea,
iodoacetamide (IAA), 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride
(DMTMM), N-Methylmorpholine (NMM), 1,4-Dimethylpiperazine (DMPipZ), anhydrous
acetonitrile, phenylmethylsulfonyl fluoride (PMSF), triethylammonium bicarbonate buffer
(TEAB), and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. Louis,
MO). Trifluoroacetic acid (TFA), formic acid (FA), DL-Dithiothreitol (DTT), and AB
Biosystems Poroszyme immobilized trypsin bulk media were purchased from Fisher (Pittsburgh,
PA). Female serum was from BioChemed (Winchester, VA). Sequence-grade trypsin was
purchased from Roche (Indianapolis, IN). Albumin and IgG depletion spin trap was from GE
Healthcare, (Westborough, MA). H218O >97% was purchased from Cambridge Isotope
Laboratories (Tewksbury, MA).

Direct-Q3 water system (Millipore, Billerica, MA) was used to purify deionized (DI) water.
Samples were dried using SpeedVac (Savant, Farmingdale, NY), vacuum oven (Fisher
Scientific, Pittsburgh, PA) or lyophilizer (Labconco, Kansas City, MO). Incubation of samples
was performed on Thermomixer R (Eppendorf, Hauppauge, NY).
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4.2.1.3. Tryptic digestion and derivatization of serum samples

To 100 μg of sample (pure serum) , 8M urea in 100 mM NH4OAc pH 8.0 buffer (100 μL)
was added and the tube was vortexed for 30 sec. Additional 100 μL of NH4OAc pH 8.0 buffer
was added to dilute the sample. Reduction was carried out by adding 4 μL of 500 mM DTE for
30 min at 30°C and let to cool down, followed by alkylation with 15 μL of 500 mM IAA for 30
min at RT in the dark. Further dilution with NH4OAc pH 8.0 buffer to a total urea concentration
of 2 M was performed prior to digestion. Trypsin was added to the sample, with an enzymesubstrate ratio of 1:25. The sample was incubated overnight at 37°C. To quench the reaction,
10% TFA was added (total TFA concentration of 2%, v/v) and incubated for 10 min. The
resulting digests were subsequently desalted using Oasis HLB material (Section 3.2.1.4),
lyophilized, and stored at -20°C. Sample-specific derivatization of digests follows same protocol
as Section 3.2.1.4.

4.2.1.4. Preparation of 18O-labeled global internal standard

Tryptic digest of 50 µL depleted serum (using depletion column as per manufacturer’s
procedure) was desalted and lyophilized. Meanwhile, 100 µL of Tris-Cl was freeze-dried and
lyophilized. About 4 mg of immobilized trypsin was weighed and washed with 5 volumes of
water three times. To the digest, 50 µL of anhydrous ACN was added and dried in the Speed
Vac. The drying procedure was repeated for a total of three times. The lyophilized Tris-Cl buffer
was reconstituted with 100 µL of H218O, producing the 18O-buffer. To the desalted digest, 20 µL
of anhydrous acetonitrile was added to dissolve the sample, followed by the addition of 30 µL of
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18

O-buffer. The sample incubated for 10 min at room temperature (without shaking or

vortexing). Additional 50 µL of 18O-buffer was added, and the sample was incubated for another
10 min. All 100 µL solution was transferred to a microcentrifuge tube containing previously
washed immobilized trypsin and incubated overnight at 37°C. After taking out from the
thermomixer, 100 µL of anhydrous ACN was added to the sample. The labeled peptides are
recovered in the supernatant following a 2 min microcentrifugation at room temperature.

4.2.2. Results and discussion

4.2.2.1. Monitoring mid-concentration proteins and the effect of peptide derivatization

The sample complexity and high dynamic range of plasma protein concentrations,
however, limit the adaption of standard chromatographic workflows in proteomic analysis
Peptide derivatization using peptidyl reagents offers signal enhancement for increased analytical
detectability in MS. In this study, peptide derivatization was performed to improve peptide signal
for proteomic profiling of human serum samples. To take advantage of the inherent signal
enhancement from derivatization data, standard flow 1D LC-MS/MS was used to evaluate the
preliminary proteomic profile.

Analysis using DDA MS of derivatized and nonderivatized tryptic serum digests
generated spectral data sets, which were then used for searching against human protein
databases. Profiles of identified mid- to high-abundance serum proteins using the developed
methods are then compared to the results from underivatized samples. Database search was
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performed in Peaks and Mascot search engine software against most recent human protein
database obtained from Uniprot. The number of proteins identified, however, was low (at most
130), which can be attributed to the use of standard LC and ESI source. Albeit the low number of
identified proteins, the search produced peptide-to-spectrum matches corresponding to
derivatized peptides. Peptidyl reagents Pr-ALG, Pr-GFG, and Pic-GGG were used for
derivatization. The identified proteins are then evaluated and quantified through a global
proteome reference. The schematic for the selection of proteins of interest from profiling data is
shown in Figure 4.1.

Figure 4.1. Selection of proteins from serum profiling preliminary results.
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4.2.2.2. Stability study for 18O-labeled global internal standard for global quantitative
applications

Various proteolytic enzymes, such as Lys-C, chymotrypsin, and Glu-C, can be used for
the enzyme-catalyzed double

18

O incorporation, provided that the same enzyme was used for

digestion. The sample must be digested in highly enriched (>95%) H218O to attain complete
double incorporation. Scheme 2 shows the mechanism for enzyme-catalyzed labeling of the
peptide. The enzyme bonds to the target residue covalently, followed by reaction with H218O
within the C-terminal. The incorporation of the second

18

O-label occurs when the enzyme

rebinds the C-terminal residue.

Scheme 2. Enzyme-catalyzed incorporation of two 18O with digestion and labeling in a single
step.
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Comparative proteomics application of the labeling technique allows for characterization
of various states at which a protein exists. A sample spectrum where the isotopic distribution
corresponds to unlabeled

16

O and labeled

18

O peptides is shown in Figure 4.2. A sample of 1:1

mixture of 16O- and 18O-labeled digest, the peak intensities I0, I2, and I4 and masses M0, M2, and
M4 are used to calculate the corrected ratio for comparative analysis.

Expected

Observed

Figure 4.2. Pair of double-charged peptides from a 1:1 mixture of 16O- and 18O-labeled digest,
showing 4 Da difference from two 18O atoms incorporated. (Adapted from Castillo, et al, a
protocol update for earlier work from University of Maryland).19

The proteolytic digestion in the first steps of digestion is solution phase, where the excess
amount of enzyme added should be inactivated or removed to prevent back-exchange. Backexchange of the oxygen labels is correlated with residual enzyme, and is an issue during storage
and sample preparations. Use of immobilized enzyme during labeling enables efficient removal
of residual in-solution enzyme. A protocol update to investigate the stability of labeled peptides,
89

and thereby the effect of residual trypsin, was performed in a separate experiment.19 The stability
of oxygen labels was investigated by storing the 18O2-labeled peptide solutions at 4°C under four
conditions for 7 days: (1) 0.2% FA, (2) 0.2% FA with 2 μM PMSF, a serine protease inhibitor,
(3) 20 mM TEAB, and (4) 20 mM TEAB with 5 μM PMSF. No measureable increases in the
signals for peptides with the single and zero 18O labels were observed for all conditions. Effect of
PMSF is not evident, which is attributed to efficient inactivation or removal of solution-phase
trypsin. Figure 4.3 shows MS spectra of a monitored peptide from buffer-stored digest sample.
BSA tryptic peptide doubly-charged LVNELTEFAK in 20 mM TEAB In Figure 4.4, no
apparent significant change was observed on the 18O/16O calculated ratios for the time course
stability investigation.

Day 0

Day 7

Figure 4.3. TOF-MS spectra of an 18O-labeled BSA tryptic peptide at Day 0 and Day 7.
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Figure 4.4. Calculated 18O/16O for time-course stability study to monitor back-exchange at
varied conditions.

Stability was recently further verified by performing a peptide level affinity pull down of
labeled standard peptide SVILLGR-[18O2], which implicates its further potential for use in
targeted quantitative proteomics.

4.2.2.3. Back to multiplexing: Deriving the N-in-1 sample throughput to analyte throughput
for global quantitative proteomics application

Proteolytic

18

O-labeling is a global, flexible, and robust technique for comparative

proteomics. A global reference internal standard was prepared out from half of the serum digest.
Proteins identified from post-derivatization samples were monitored in standard LC MRM MS.
Table 4.1 lists the selected peptides and the endogenous to internal standard ratios obtained. A
number of peptides yielded ratios close to 1, deeming them as putative surrogate peptides for
quantitation. Also shown are the concentrations of the corresponding protein from literature.
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Increasing the coverage and reducing the sample complexity are essential for a global
quantitative approach. An initiated study on combining uMRM and cysteinyl peptide enrichment
wherein reduction of sample complexity is made possible via biotinylation and avidin sizeexclusion filtration, will enable such analysis. A recently developed technique, called CysTRAQ
integrates iTRAQ and enrichment of cysteinyl peptides for uncovering and quantifying hidden
proteomes.20 Contrasting with the N-in-1 uMRM MS workflow previously shown in Figure 3.1,
Figure 4.5 presents the transformed analytical technique for analyzing a number of selected
proteins in multiple serum samples. Realization of the combined will be beneficial in the early
stage analysis within the biomarker pipeline without the need for antibodies. In addition,
replicate experiments in one analysis can be performed through peptide derivatizations.
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Table 4.1. Comparative quantitation investigation of monitored peptides from serum proteome
using 18O-labeled global reference standard.
Conc. From
Protein

Peptide

Literature
(ng/mL)12

Alpha-1-antitrypsin

Ratio
(Endogenous/IS)

ITPNLAEFAFSLYR

No data

ND

LQHLENELTHDIITK

No data

1.75

LSITGTYDLK

6.1E+06

ND

SVLGQLGITK

1.1E+06

1.31

VFSNGADLSGVTEEAPLK 3.6E+05

1.18

Clusterin

ELDESLQVAER

2.0E+05

1.01

Haptoglobin

DIAPTLTLYVGK

4.6E+05

0.51

HYEGSTVPEK

1.3E+05

0.47

VGYVSGWGR

1.3E+06

3.46

NWGLSVYADKPETTK

1.8E+02

1.18

Pregnancy zone protein ISEITNIVSK

7.3E+03

ND

Beta-2-glycoprotein 1

ATVVYQGER

2.1E+05

ND

ADLFYDVEALDLESPK

1.8E+06

0.96

DGYLFQLLR

7.0E+04

ND

GGEGTGYFVDFSVR

1.0E+06

1.08

ATEHLSTLSEK

1.0E+06

1.58

DLATVYVDVLK

8.7E+05

1.26

VQPYLDDFQK

2.3E+05

0.80

VSFLSALEEYTK

9.7E+04

1.41

Hemopexin

NFPSPVDAAFR

4.0E+05

0.84

Ceruloplasmin

DIFTGLIGPMK

2.0E+01

1.85

Alpha-1-acid
glycoprotein 1

Histidine-rich
glycoprotein

Apolipoprotein A-I
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Figure 4.5. Cysteinyl peptide enrichment workflow.
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Chapter 5. Conclusions and perspectives

With sample-specific, non-isotopic derivatization of digests of human biological samples,
ultrathroughput mass spectrometry (uMS) was developed for targeted quantitative proteomics.
Intrinsic analyte multiplexing capability of mass spectrometry was leveraged to achieve sample
multiplexing that will break through the sample-throughput bottleneck of current mass
spectrometry methods. The novel bioanalytical platform integrates non-isotopic peptide
derivatization, single peptide-level enrichment technique, and MRM MS analysis to perform Nin-1 quantitation of signature peptides from low-abundant proteins. Peptidyl reagents were
prepared for uMS screening to identify reagents that enable high signal yield in mass
spectrometry. Using these reagents for sample-specific derivatizations, one-experiment
quantitation of multiple serum samples containing common, low-abundance prostate specific
antigen was demonstrated.

The open-source design of uMRM MS technology offers facile adaptability for
improving the sample throughput in protein biomarker validation and the flexibility of the assay
across different candidates. A repository of peptidyl reagents with high signal enhancement
capabilities was obtained from screening of more than a thousand of reagents. The novel
bioanalytical platform presented minimum utilization of isotope labels and does not require
immunograde antibodies, unlike current immunoassay validation gold standards. Moreover,
sample complexity and dilution issues are mitigated by the peptide-level affinity-based
preparation, enabling the elimination of preliminary depletion of high-abundance serum proteins
in the upstream sample processing.

97

With the signal-enhancing advantages, analyte throughput, and enrichment capabilities,
uMRM has the potential to further present an interesting application: to analyze protein
biomarker panels in multiple samples. This integration of multiplexing and sample throughput
dimensions, a current undertaking in the laboratory, will provide multiplexed N-in-1 approach
that will further expand the utility of uMS approach in the biomarker development.

The peptide-specific signal enhancement properties of the derivatization were further
exploited for global quantitative proteomics application. A proof-of-concept study analyzed
human serum proteins with standard flow LC-MS instrumentation. A universal reference serum
proteome standard was prepared for the analysis using 18O labeling. These studies will then help
commence the advancement of the technology for measuring biomarker candidates in larger
number of clinical serum samples. Future work on this novel technology can also be directed
towards the evaluation of candidate protein biomarkers across different forms of cancer and
other complex diseases, and find important implementation in clinical cancer researches.
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Appendix
Appendix 1: MS Screening data for peptide CFTR01 derivatization with library of peptidyl
reagents

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

LC-TOF-MS Analysis, Peak Height
Peptidyl Reagent
CFTR01
Short
N-terminal
SYMS, %
peptide
modification
sequence
Dim
βAVF
4.4E+02
Dim
LAA
2.9E+02
Dim
LVL
2.1E+02
Dim
LAL
2.4E+02
Dim
LVG
6.4E+02
Dim
LAG
5.4E+02
Dim
LVF
2.1E+02
Dim
LAF
2.8E+02
Dim
LAV
4.4E+02
Dim
FAV
1.3E+02
Dim
FAA
1.7E+02
Dim
FAL
1.5E+02
Dim
FAG
1.2E+02
Dim
FAF
4.1E+02
Dim
FLG
1.6E+02
Dim
FVL
1.4E+02
Dim
VLF
1.2E+02
Dim
VFV
1.7E+02
Dim
LLF
1.1E+02
Dim
LFF
1.4E+02
Dim
LFV
2.3E+02

1
2
3
4

NanoLC-MRM-MS Analysis, Peak Area
Peptidyl Reagent
CFTR01
Short
N-terminal
SYMS, %
peptide
modification
sequence
Dim
LFA
7.5E+02
Dim
LGA
1.2E+03
Dim
FGV
1.4E+02
Dim
FLV
1.5E+03
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(Cont’d.)
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

NanoLC-MRM-MS Analysis, Peak Area
Peptidyl Reagent
CFTR01
Short
N-terminal
SYMS, %
peptide
modification
sequence
Dim
FFA
1.1E+04
Dim
FLA
8.9E+02
Dim
FLL
3.6E+02
Dim
FLF
3.5E+02
Dim
VGV
1.4E+02
Dim
VLV
1.7E+02
Dim
VFA
1.1E+03
Dim
VGA
6.7E+02
Dim
VLA
8.7E+02
Dim
VGG
9.6E+02
Dim
VLG
9.7E+02
Dim
VFF
5.7E+02
Dim
AFV
4.6E+02
Dim
AGF
4.7E+02
Dim
AGG
1.8E+02
Dim
ALG
2.3E+02
Pr
AFA
1.2E+03
Pr
AGA
6.9E+02
Pr
ALA
5.0E+02
Pr
AFG
5.0E+02
Pr
ALG
1.3E+02
Pr
AFF
3.1E+02
Pr
AGF
7.8E+02
Pr
ALF
4.2E+02
Pr
VFA
1.2E+03
Pr
VGA
1.1E+03
Pr
VLA
1.1E+03
Pr
VGG
2.5E+02
Pr
VLG
3.5E+02
Pr
FGV
1.7E+02
Pr
FGA
2.1E+03
Pr
FLA
1.0E+03
Pr
FGG
2.8E+02
Pr
FGF
1.8E+03
Gl
FFA
8.8E+02
Gl
FGA
1.1E+03
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(Cont’d.)
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76

NanoLC-MRM-MS Analysis, Peak Area
Peptidyl Reagent
CFTR01
Short
N-terminal
SYMS, %
peptide
modification
sequence
Gl
FLA
3.7E+02
Gl
FGG
2.1E+02
Gl
FFF
4.1E+02
OPA
VFA
2.9E+02
OPA
VGA
2.0E+02
OPA
VLA
3.1E+02
OPA
VFF
1.7E+02
OPA
VLF
1.9E+02
Pic
GFA
2.6E+02
Pic
GGA
7.4E+02
Pic
GLA
2.0E+02
Pic
GFG
1.6E+02
Pic
GGG
5.6E+02
Pic
GLG
2.7E+02
Pic
GGF
3.5E+02
Pic
GLF
1.4E+02
Dim
VAGL
4.0E+02
Dim
VAGF
6.2E+02
Dim
VGAG
4.1E+02
Dim
VGVL
5.0E+02
Dim
VGVF
8.3E+02
Dim
VGVG
4.6E+02
Dim
VGVV
3.5E+02
Dim
VGAA
5.5E+02
Dim
VGVA
8.5E+02
Dim
GAAL
2.6E+02
Dim
GAAF
4.8E+02
Dim
GAVL
1.5E+02
Dim
GAVF
2.8E+02
Dim
GAVV
4.2E+02
Dim
GAAA
3.2E+02
Dim
GAVA
5.5E+02
Dim
AFAL
8.8E+02
Dim
AFAF
1.4E+03
Dim
AFAG
5.5E+02
Dim
AFVL
9.1E+02
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(Cont’d.)
77
78
79
80
81

NanoLC-MRM-MS Analysis, Peak Area
Peptidyl Reagent
CFTR01
Short
N-terminal
SYMS, %
peptide
modification
sequence
Dim
AFVF
1.3E+03
Dim
AFVG
4.7E+02
Dim
AFVV
1.8E+02
Dim
AFAA
1.6E+03
Dim
AFVA
1.3E+03
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Appendix 2: MS Screening data for peptide SVI derivatization with library of peptidyl reagents

LC-TOF-MS Analysis, Peak Height
Peptidyl Reagent
SVI SYMS,
N-terminal Short peptide
%
modification
sequence
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr
Pr

GFV
GGV
GLV
GFA
GLF
LGV
LFA
LGA
LLA
LFG
LGG
LLG
LLV
VFA
VGA
VLA
VFG
VGG
VLG
VGF
AFA
AGA
ALA
AFG
AGG
ALG
AGF
GGA
GLA
GFG
GGG
GLG
GFF

5.7E+02
1.4E+02
2.8E+03
5.3E+03
3.0E+02
1.4E+02
1.0E+02
8.8E+02
1.9E+02
1.8E+02
4.0E+02
1.6E+02
1.8E+02
3.0E+02
5.1E+02
2.4E+02
2.0E+02
3.0E+02
2.2E+02
2.0E+02
4.8E+02
1.1E+03
5.7E+02
3.5E+02
2.5E+02
2.8E+02
3.5E+02
4.8E+03
2.5E+03
8.7E+02
1.8E+03
1.1E+02
2.5E+03
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(Cont’d.)
34
35
36
37
38
39
40
41
42

LC-TOF-MS Analysis, Peak Height
Peptidyl Reagent
SVI SYMS,
N-terminal Short peptide
%
modification
sequence
Pr
Pic
Pic
Pic
Pic
Pic
Dim
Dim
Dim

GGF
GGA
GFG
GGG
GLG
GGF
FVVF
FVAV
FVVA

3.0E+02
8.5E+02
3.3E+02
1.2E+03
3.9E+02
3.0E+02
1.1E+02
3.4E+03
2.6E+03

NanoLC-MRM-MS Analysis, Peak Area
Peptidyl Reagent
SVI SYMS,
N-terminal
Short peptide
%
modification
sequence
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim
Dim

AVA
AVG
AAV
AAA
AAG
VVG
VAV
VAA
VAL
VAG
VAF
GVA
GVG
GVF
GAV
GAA
GAL
GAG
GAF
LFG
LVG

2.8E+02
6.4E+02
4.1E+02
1.9E+02
5.4E+02
1.7E+03
7.0E+02
1.0E+03
3.0E+02
1.4E+03
5.3E+02
4.6E+02
6.3E+02
2.2E+02
7.0E+02
4.0E+02
1.3E+02
1.0E+03
5.0E+02
1.5E+03
1.4E+03
104

(Cont’d.)
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

NanoLC-MRM-MS Analysis, Peak Area
Peptidyl Reagent
Short
SVI SYMS, %
N-terminal
peptide
modification
sequence
Dim
GLL
1.1E+03
Dim
GLG
1.7E+02
Dim
GFL
1.1E+03
Dim
GFG
1.8E+02
Dim
GVL
6.3E+02
Dim
FVAF
2.3E+03
Dim
FVAL
1.2E+03
Dim
FVVL
8.0E+02
Dim
FVVG
8.6E+02
Dim
FVAA
3.9E+03
Dim
GLVV
3.0E+03
Dim
GLAA
2.8E+03
Dim
GVVV
2.7E+02
Dim
βAAVG
2.1E+03
Dim
βAVAF
2.6E+03
Dim
bAL
1.1E+03
Dim
bAG
8.4E+02
Dim
bAA
3.8E+02
Pr
LLV
1.4E+02
Pr
FVAA
1.1E+02
Pr
FVVL
2.0E+02
Pr
AFVG
7.0E+02
Pr
AFAG
3.6E+02
Pr
AFAF
1.2E+02
Pr
AFAL
1.4E+02
Pr
GLGG
1.0E+03
Pr
GLLL
4.9E+02
Pr
GLFF
4.7E+02
Pr
GVFF
3.5E+02
Pr
GLAA
2.2E+03
Pr
VLGG
1.2E+03
Pr
VLAA
8.3E+02
Pr
LLGG
7.2E+02
Pr
LVGG
3.9E+02
Pr
LVAA
6.4E+02
Pr
ALVV
7.4E+02
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(Cont’d.)
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93

NanoLC-MRM-MS Analysis, Peak Area
Peptidyl Reagent
Short
SVI SYMS, %
N-terminal
peptide
modification
sequence
Pr
FAFV
1.5E+02
Pr
FALV
4.8E+02
Pr
FAGF
3.4E+02
Pr
AGVG
1.4E+02
Pr
GLAG
2.0E+02
Pr
GLFG
2.6E+02
Pr
GAVV
9.5E+02
Pic
AFVA
2.7E+02
Pic
AFAA
5.5E+02
Pic
AFVV
2.6E+02
Pic
AFVG
3.8E+02
Pic
AFAG
4.4E+02
Pic
AFAL
1.5E+02
Pic
AFAF
1.1E+02
Pic
VGAA
9.0E+02
Pic
VGAF
5.2E+02
Pic
VGVG
1.7E+03
Pic
VGAG
3.3E+02
Pic
GLGG
1.7E+03
Pic
GLFF
1.3E+02
Pic
GVGG
3.9E+02
Pic
GVFF
1.6E+02
Pic
LLGG
1.4E+03
Pic
LVGG
6.1E+02
Pic
VLGG
2.7E+03
Pic
VVAA
3.6E+02
Pic
VVGG
7.9E+02
Pic
VLAA
1.9E+02
DEABA
GGG
1.1E+02
DEABA
GLG
1.8E+02
Gl
AFVL
1.6E+03
Gl
AFVF
1.2E+03
Gl
AFVG
2.9E+02
Gl
AFAV
1.7E+03
Gl
GAAL
3.7E+02
Gl
GAAG
3.1E+02
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(Cont’d.)
94
95
96
97
98
99
100
101
102
103

NanoLC-MRM-MS Analysis, Peak Area
Peptidyl Reagent
Short
SVI SYMS, %
N-terminal
peptide
modification
sequence
Ac
FVG
5.9E+02
Ac
FFG
2.8E+02
Ac
FLG
2.4E+02
Ac
FLL
1.1E+02
Ac
VVV
1.7E+02
Ac
VLV
1.4E+02
Ac
βAVL
1.1E+03
Ac
βAVF
3.4E+02
Ac
βAGL
4.8E+02
Ac
βAGF
1.1E+02
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